Clarivate (CLVT) 10-Q 7 Aug 23 2023 FY Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Document Information [Line Items]
Document Type	10-Q
Document Period End Date	Jun. 30, 2023
Document Quarterly Report	true
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-38911
Entity Registrant Name	CLARIVATE PLC
Entity Incorporation, State or Country Code	Y9
Entity Address, Address Line One	70 St. Mary Axe
Entity Address, City or Town	London
Entity Address, Postal Zip Code	EC3A 8BE
Entity Address, Country	GB
Country Region	44
City Area Code	207
Local Phone Number	4334000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		676,234,313
Entity Central Index Key	0001764046
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Tax Identification Number	00-0000000
Ordinary Shares
Document Information [Line Items]
Trading Symbol	CLVT
Security Exchange Name	NYSE
Title of 12(b) Security	Ordinary Shares, no par value
Series A Preferred Stock
Document Information [Line Items]
Trading Symbol	CLVT PR A
Security Exchange Name	NYSE
Title of 12(b) Security	5.25% Series A Mandatory Convertible Preferred Shares, no par value
Preferred Stock Purchase Rights
Document Information [Line Items]
Security Exchange Name	NYSE
Title of 12(b) Security	Series B Preferred Stock Purchase Rights

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 436.1	$ 348.8
Restricted cash	7	8
Accounts receivable, net	769.7	872.1
Prepaid expenses	101.9	89.4
Other current assets	76.8	76.9
Assets held for sale	26.1	0
Total current assets	1,417.6	1,395.2
Property and equipment, net	50.7	54.5
Other intangible assets, net	9,186.4	9,437.7
Goodwill	2,895.5	2,876.5
Other non-current assets	76	97.9
Deferred income taxes	26.5	24.2
Operating lease right-of-use assets	52.9	58.9
Total Assets	13,705.6	13,944.9
Current liabilities:
Accounts payable	108.2	101.4
Accrued compensation	101.2	132.1
Accrued expenses and other current liabilities	317.1	352.1
Current portion of deferred revenues	939.6	947.5
Current portion of operating lease liability	24.2	25.7
Current portion of long-term debt	1.1	1
Liabilities held for sale	6.5	0
Total current liabilities	1,497.9	1,559.8
Long-term debt	4,863.2	5,005
Non-current portion of deferred revenues	37.9	38.5
Other non-current liabilities	41.4	140.1
Deferred income taxes	262.1	316.1
Operating lease liabilities	64.8	72.9
Total liabilities	6,767.3	7,132.4
Shareholders’ equity:
Preferred Shares, no par value; 14.4 shares authorized; 5.25% Mandatory Convertible Preferred Shares, Series A, 14.4 shares issued and outstanding as of both June 30, 2023 and December 31, 2022	1,392.6	1,392.6
Ordinary Shares, no par value; unlimited shares authorized at June 30, 2023 and December 31, 2022; 676.1 and 674.4 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	11,809.2	11,744.7
Accumulated other comprehensive loss	(487.6)	(665.9)
Accumulated deficit	(5,775.9)	(5,658.9)
Total shareholders’ equity	6,938.3	6,812.5
Total Liabilities and Shareholders’ Equity	$ 13,705.6	$ 13,944.9

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized (in shares)	14.4	14.4
Preferred stock, dividend rate (as a percent)	5.25%	5.25%
Preferred stock, issued (in shares)	14.4	14.4
Preferred stock, outstanding (in shares)	14.4	14.4
Ordinary shares, par value (in dollars per share)	$ 0	$ 0
Ordinary shares, issued (in shares)	676.1	674.4
Ordinary shares, outstanding (in shares)	676.1	674.4

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues, net	$ 668.8	$ 686.6	$ 1,297.9	$ 1,348.8
Operating Expenses:
Cost of revenues	224.2	244.1	453.9	493.3
Selling, general and administrative costs	192.9	186.1	387.7	379.8
Depreciation and amortization	178.1	175.6	350.7	352
Restructuring and impairment	12.2	19.2	21.6	30.9
Goodwill and intangible asset impairments	135.2	0	135.2	0
Other operating income, net	14.5	(24.6)	(17.5)	(38.3)
Total operating expenses	757.1	600.4	1,331.6	1,217.7
(Loss) income from operations	(88.3)	86.2	(33.7)	131.1
Mark to market (gain) loss on financial instruments	(2.9)	(49)	(1.8)	(149.4)
Interest expense and amortization of debt discount, net	73	62.3	146.6	121.8
Income (loss) before income taxes	(158.4)	72.9	(178.5)	158.7
(Benefit) provision for income taxes	(35.3)	10.5	(98.9)	26.8
Net (loss) income	(123.1)	62.4	(79.6)	131.9
Dividends on preferred shares	18.6	18.7	37.4	37.4
Net income (loss) attributable to ordinary shares	$ (141.7)	$ 43.7	$ (117)	$ 94.5
Earnings per share
Basic (usd per share)	$ (0.21)	$ 0.06	$ (0.17)	$ 0.14
Diluted (usd per share)	$ (0.21)	$ 0	$ (0.17)	$ (0.07)
Weighted average shares used to compute earnings per share:
Basic (in shares)	675.9	674.3	675.4	678.3
Diluted (in shares)	675.9	678.4	675.4	683.2

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (123.1)	$ 62.4	$ (79.6)	$ 131.9
Other comprehensive income (loss), net of tax:
Interest rate swaps	7.3	3.9	(5.1)	15.8
Foreign currency translation adjustment	82.6	(626.6)	183.4	(861.7)
Total other comprehensive income (loss), net of tax	89.9	(622.7)	178.3	(845.9)
Comprehensive income (loss)	$ (33.2)	$ (560.3)	$ 98.7	$ (714)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Ordinary Shares	Preferred Shares	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock, Common
Increase (Decrease) in Shareholders' Equity
Treasury Stock, Common, Shares						500,000
Balance at beginning of the period (in shares) at Dec. 31, 2021		683,100,000	14,400,000
Balance at beginning of the period at Dec. 31, 2021	$ 11,925.9	$ 11,827.9	$ 1,392.6	$ 326.7	$ (1,604.4)
Balance at beginning of the period at Dec. 31, 2021						$ 16.9
Increase (Decrease) in Shareholders' Equity
Reclassification of EBT Shares		(500,000)
Exercise of stock options (in shares)		200,000
Exercise of stock options	0.4	$ 0.4
Vesting of restricted stock units (in shares)		700,000
Share-based award activity (in shares)		(400,000)
Share-based award activity	21.5	$ 21.5
Repurchase of ordinary shares (in shares)		(4,100,000)				(4,100,000)
Repurchases of ordinary shares	(66.4)					$ (66.4)
Retirement of treasury shares (in shares)						(2,100,000)
Retirement of treasury shares		$ (34.8)			1.5	$ 33.3
Sale of treasury shares (in shares)						0
Sale of treasury shares	0.6				(0.7)	$ 1.3
Dividends to preferred shareholders	(18.7)				(18.7)
Net income (loss)	69.5				69.5
Other comprehensive income (loss)	(223.2)			(223.2)
Balance at end of the period (in shares) at Mar. 31, 2022		679,000,000	14,400,000
Balance at end of the period at Mar. 31, 2022	11,709.6	$ 11,815	$ 1,392.6	103.5	(1,552.8)
Balance at end of the period at Mar. 31, 2022						(48.7)
Balance at beginning of the period (in shares) at Dec. 31, 2021		683,100,000	14,400,000
Balance at beginning of the period at Dec. 31, 2021	$ 11,925.9	$ 11,827.9	$ 1,392.6	326.7	(1,604.4)
Balance at beginning of the period at Dec. 31, 2021						16.9
Increase (Decrease) in Shareholders' Equity
Repurchase of ordinary shares (in shares)	(10,700,000)
Repurchases of ordinary shares	$ (175)
Retirement of treasury shares (in shares)	(10,700,000)
Retirement of treasury shares	$ (167.3)				(7.7)	175
Sale of treasury shares (in shares)	41,700
Sale of treasury shares					(0.7)
Net income (loss)	$ 131.9
Other comprehensive income (loss)	(845.9)
Balance at end of the period (in shares) at Jun. 30, 2022			14,400,000
Balance at end of the period at Jun. 30, 2022	11,040.7	$ 11,700.9	$ 1,392.6	(519.2)	(1,518)
Balance at end of the period at Jun. 30, 2022						$ (15.6)
Increase (Decrease) in Shareholders' Equity
Treasury Stock, Common, Shares						2,500,000
Balance at beginning of the period (in shares) at Mar. 31, 2022		679,000,000	14,400,000
Balance at beginning of the period at Mar. 31, 2022	11,709.6	$ 11,815	$ 1,392.6	103.5	(1,552.8)
Balance at beginning of the period at Mar. 31, 2022						$ (48.7)
Increase (Decrease) in Shareholders' Equity
Exercise of stock options (in shares)		0
Exercise of stock options	0.1	$ 0.1
Vesting of restricted stock units (in shares)		(1,300,000)
Share-based award activity (in shares)		(400,000)
Share-based award activity	18.3	$ 18.3
Repurchase of ordinary shares (in shares)		(6,600,000)				(6,600,000)
Repurchases of ordinary shares	(108.6)					$ (108.6)
Retirement of treasury shares (in shares)		0				(8,600,000)
Retirement of treasury shares		$ (132.5)			(9.2)	$ 141.7
Sale of treasury shares (in shares)		0				0
Sale of treasury shares	0.3				0.3	$ 0
Dividends to preferred shareholders (in shares)		0
Dividends to preferred shareholders	(18.7)	$ 0			(18.7)
Net income (loss)	62.4				62.4
Other comprehensive income (loss)	(622.7)			(622.7)
Balance at end of the period (in shares) at Jun. 30, 2022			14,400,000
Balance at end of the period at Jun. 30, 2022	$ 11,040.7	$ 11,700.9	$ 1,392.6	(519.2)	(1,518)
Balance at end of the period at Jun. 30, 2022						$ (15.6)
Increase (Decrease) in Shareholders' Equity
Treasury Stock, Common, Shares						500,000
Treasury Stock, Common, Shares	0					0
Balance at beginning of the period (in shares) at Dec. 31, 2022		674,400,000	14,400,000
Balance at beginning of the period at Dec. 31, 2022	$ 6,812.5	$ 11,744.7	$ 1,392.6	(665.9)	(5,658.9)
Balance at beginning of the period at Dec. 31, 2022						$ 0
Increase (Decrease) in Shareholders' Equity
Vesting of restricted stock units (in shares)		1,800,000
Share-based award activity (in shares)		(600,000)
Share-based award activity	33.7	$ 33.7
Dividends to preferred shareholders	(18.8)				(18.8)
Net income (loss)	43.5				43.5
Other comprehensive income (loss)	88.4			88.4
Balance at end of the period (in shares) at Mar. 31, 2023		675,600,000	14,400,000
Balance at end of the period at Mar. 31, 2023	6,959.3	$ 11,778.4	$ 1,392.6	(577.5)	(5,634.2)
Balance at end of the period at Mar. 31, 2023						0
Balance at beginning of the period (in shares) at Dec. 31, 2022		674,400,000	14,400,000
Balance at beginning of the period at Dec. 31, 2022	6,812.5	$ 11,744.7	$ 1,392.6	(665.9)	(5,658.9)
Balance at beginning of the period at Dec. 31, 2022						0
Increase (Decrease) in Shareholders' Equity
Retirement of treasury shares	0
Net income (loss)	(79.6)
Other comprehensive income (loss)	178.3
Balance at end of the period (in shares) at Jun. 30, 2023		676,100,000	14,400,000
Balance at end of the period at Jun. 30, 2023	6,938.3	$ 11,809.2	$ 1,392.6	(487.6)	(5,775.9)
Balance at end of the period at Jun. 30, 2023						$ 0
Increase (Decrease) in Shareholders' Equity
Treasury Stock, Common, Shares						0
Balance at beginning of the period (in shares) at Mar. 31, 2023		675,600,000	14,400,000
Balance at beginning of the period at Mar. 31, 2023	6,959.3	$ 11,778.4	$ 1,392.6	(577.5)	(5,634.2)
Balance at beginning of the period at Mar. 31, 2023						$ 0
Increase (Decrease) in Shareholders' Equity
Vesting of restricted stock units (in shares)		800,000
Share-based award activity (in shares)		(300,000)
Share-based award activity	30.8	$ 30.8
Dividends to preferred shareholders	(18.6)				(18.6)
Net income (loss)	(123.1)				(123.1)
Other comprehensive income (loss)	89.9			89.9
Balance at end of the period (in shares) at Jun. 30, 2023		676,100,000	14,400,000
Balance at end of the period at Jun. 30, 2023	$ 6,938.3	$ 11,809.2	$ 1,392.6	$ (487.6)	$ (5,775.9)
Balance at end of the period at Jun. 30, 2023						$ 0
Increase (Decrease) in Shareholders' Equity
Treasury Stock, Common, Shares	0					0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows From Operating Activities
Net income (loss)	$ (79.6)	$ 131.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	350.7	352
Deferred Income Taxes and Tax Credits	(47.8)	(0.9)
Share-based compensation	71.6	47.2
Restructuring and impairments	138.7	(1)
Mark to market gain on financial instruments	(1.8)	(149.4)
Amortization of debt issuance costs	9.1	7.6
Gain on legal settlement	(49.4)	0
Other operating activities	18.8	(33.6)
Changes in operating assets and liabilities:
Accounts receivable	121.7	53.8
Prepaid expenses	(11.9)	(26.9)
Other assets	38.6	(24.8)
Accounts payable	6.2	(8.8)
Accrued expenses and other current liabilities	(74.2)	(150.3)
Deferred revenues	(18.4)	(29.5)
Operating leases, net	(4.5)	3.4
Other liabilities	(77.9)	(6.1)
Net cash provided by operating activities	389.9	164.6
Cash Flows From Investing Activities
Capital expenditures	(116.9)	(89.1)
Payments for acquisitions and cost method investments, net of cash acquired	(1.1)	(14.3)
Proceeds from divestitures, net of cash and restricted cash	10.5	0
Net cash used in investing activities	(107.5)	(103.4)
Cash Flows From Financing Activities
Principal payments on term loan	(150)	(14.3)
Payment of debt issuance costs and discounts	0.1	2.1
Proceeds from issuance of treasury shares	0	0.9
Repurchases of ordinary shares	0	(175)
Cash dividends on preferred shares	(37.7)	(37.7)
Proceeds from stock options exercised	0	0.5
Payments related to finance lease	(0.5)	(1)
Payments related to tax withholding for stock-based compensation	(9.7)	(10.7)
Net cash used in financing activities	(197.8)	(239.4)
Effects of exchange rates	1.7	(36.5)
Net increase (decrease) in cash and cash equivalents	87.3	(71.2)
Net decrease in restricted cash	(1)	(143.5)
Net increase (decrease) in cash and cash equivalents, and restricted cash	86.3	(214.7)
Cash and cash equivalents, beginning of period	348.8	430.9
Restricted cash, beginning of period	8	156.7
Total cash and cash equivalents, and restricted cash, beginning of period	356.8	587.6
Cash and cash equivalents, end of period	436.1	359.7
Restricted cash, end of period	7	13.2
Total cash and cash equivalents, and restricted cash, end of period	443.1	372.9
Supplemental Cash Flow Information:
Cash paid for interest	136.4	113.4
Cash paid for income tax	22.5	23.7
Capital expenditures included in accounts payable	10.3	23.8
Non-Cash Financing Activities:
Stock repurchased and retired	0	167.3
Total Non-Cash Financing Activities	6.2	(168.8)
Treasury Stock, Common
Non-Cash Financing Activities:
Stock repurchased and retired		(175)
Series A Preferred Stock
Non-Cash Financing Activities:
Dividends accrued on our 5.25% Series A Mandatory Convertible Preferred Shares	$ 6.2	$ 6.2

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Preferred stock, dividend rate (as a percent)	5.25%	5.25%

Background and Nature of Operat

Background and Nature of Operations	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Nature of Operations	Background and Nature of Operations Clarivate Plc (“Clarivate,” “us,” “we,” “our,” or the “Company”), is a public limited company organized under the laws of Jersey, Channel Islands, pursuant to the definitive agreement entered into on May 13, 2019 to effect a merger between Camelot Holdings (Jersey) Limited ("Jersey") and Churchill Capital Corp, a Delaware corporation ("Churchill") (the “2019 Transaction”). The Company is a provider of proprietary and comprehensive information, analytics, professional services and workflow solutions that enable users across government and academic institutions, life science and healthcare companies, corporations and law firms to power the entire innovation lifecycle, from cultivating curiosity to protecting the world's critical intellectual property assets. Clarivate has three reportable segments: Academia & Government ("A&G"), Intellectual Property ("IP"), and Life Sciences & Healthcare ("LS&H"). Our segment structure is organized based on the products we offer and the markets they serve. See Note 16 - Segment Information, for additional information on the Company's reportable segments.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements of the Company have been prepared on substantially the same basis as our annual consolidated financial statements and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022. Results from interim periods should not be considered indicative of results for the full year. In the opinion of management, these Condensed Consolidated Financial Statements reflect all adjustments necessary for a fair statement of financial position, results of operations, and cash flows for the periods presented, and such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements of the Company include the accounts of all of its subsidiaries. Subsidiaries are entities over which the Company has control, where control is defined as the power to govern financial and operating policies. Generally, the Company has a shareholding of more than 50% of the voting rights in its subsidiaries. The effect of potential voting rights that are currently exercisable is considered when assessing whether control exists. Subsidiaries are fully consolidated from the date control is transferred to the Company, and are de-consolidated from the date control ceases. Intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Our significant accounting policies are those that we believe are important to the portrayal of our financial condition and results of operations, as well as those that involve significant judgments or estimates about matters that are inherently uncertain. There have been no material changes to the significant accounting policies discussed in Item 8. Financial Statements and Supplementary Data – Notes to the Consolidated Financial Statements – Note 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 1, 2023. Newly Adopted Accounting Standards In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform between March 12, 2020 and December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope , which provides additional optional guidance on the transition from LIBOR to include derivative instruments that use an interest rate for margining, discounting or contract price alignment. The standard will ease, if warranted, the requirements for accounting for the future effects of the rate reform. Additionally, in December 2022, the FASB issued ASU 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024 to align with the amended cessation date of LIBOR. In 2020, the Company adopted ASU 2020-04, and, upon meeting the specified criteria in the guidance, elected the optional expedients for its interest rate swaps and debt agreements with reference to LIBOR. Accordingly, the Company has continued to account for its interest rate swaps in accordance with hedge accounting and has not applied modification accounting to its debt agreements. ASU 2021-01 and ASU 2022-06 did not have an effect on how the Company accounts for its interest rate swaps and debt agreements due to our election and application of the optional expedients discussed above in connection with ASU 2020-04. During the second quarter of 2023, the Company modified the contractual terms of its interest rate swaps and debt agreements to replace the previous LIBOR-based reference rate with the Term SOFR (Secured Overnight Financing Rate). The Company utilized the practical expedients set forth in Topic 848 and has continued to account for its interest rate swaps in accordance with hedge accounting and has not applied modification accounting to its debt instruments. Recently Issued Accounting Standards There were no other new accounting standards or updates issued or effective as of June 30, 2023, that have, or are expected to have, a material impact on the Company's Condensed Consolidated Financial Statements.

Assets Held for Sale and Divest

Assets Held for Sale and Divested Operations	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Assets Held for Sale and Divested Operations	Note 4: Assets Held for Sale and Divested Operations During the second quarter 2023, the Company entered into a commercial agreement to sell a small product group within its IP segment for approximately $34 payable over ten years. The divestiture enables improved focus on our core IP business assets and empowers product development and innovation teams to build upon our market-leading IP intelligence, IP lifecycle management and IP services solutions. The transaction, which is expected to close during the fourth quarter of 2023, does not represent a strategic shift, nor is it expected to have a material impact on the Company’s operations or financial results. Accordingly, the divestiture meets the held-for-sale criteria but does not qualify as a discontinued operation as of June 30, 2023. Prior to the held-for-sale determination and accompanying impairment testing as of June 30, 2023, the carrying amount of the expected assets to be disposed of consisted almost entirely of purchase-related identifiable customer relationship intangible assets of approximately $158. These intangible assets were reduced to estimated fair value of $26.1 based on the estimated present value of the consideration to be paid over ten years and were reclassified to Assets held-for-sale on the Condensed Consolidated Balance Sheet as of June 30, 2023. The related impairment charge of $132.2 is included in Goodwill and intangible asset impairments in the Condensed Consolidated Statement of Operations. The carrying amount of the expected liabilities to be transferred consisted of the remaining deferred tax liabilities associated with those intangibles of $6.5, which were reclassified to Liabilities held-for-sale on the Condensed Consolidated Balance Sheet as of June 30, 2023. On October 31, 2022, the Company completed the sale of the MarkMonitor Domain Management business (IP segment) to Newfold Digital, a leading web presence solutions provider. During the second quarter 2023, the Company received the $10.5 of deferred closing consideration included in the aggregate sale price.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consisted of the following: June 30, December 31, 2023 2022 Computer hardware $ 49.3 $ 45.1 Leasehold improvements 15.6 16.1 Furniture, fixtures and equipment 42.0 39.0 Capital office leases - finance lease asset 8.0 8.0 Other 2.2 2.1 Total property and equipment, gross $ 117.1 $ 110.3 Accumulated depreciation (66.4) (55.8) Total property and equipment, net $ 50.7 $ 54.5 Depreciation expense was $5.4 and $9.8 for the three months ended June 30, 2023 and 2022, respectively, and $11.3 and $20.4 for the six months ended June 30, 2023 and 2022, respectively.

Other Intangible Assets, net an

Other Intangible Assets, net and Goodwill	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets, net and Goodwill	Other Intangible Assets, net and Goodwill Other Intangible Assets, net The following tables summarize the gross carrying amounts and accumulated amortization of the Company’s identifiable intangible assets by major class: June 30, 2023 December 31, 2022 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Finite-lived intangible assets: Customer relationships $ 7,778.4 $ (994.7) $ 6,783.7 $ 7,809.0 $ (821.5) $ 6,987.5 Databases and content 2,733.7 (889.7) 1,844.0 2,681.0 (780.5) 1,900.5 Computer software 828.2 (469.2) 359.0 765.1 (422.2) 342.9 Other 88.7 (45.9) 42.8 88.8 (38.9) 49.9 Finite-lived intangible assets $ 11,429.0 $ (2,399.5) $ 9,029.5 $ 11,343.9 $ (2,063.1) $ 9,280.8 Indefinite-lived intangible assets: Trade names 156.9 — 156.9 156.9 — 156.9 Total intangible assets $ 11,585.9 $ (2,399.5) $ 9,186.4 $ 11,500.8 $ (2,063.1) $ 9,437.7 Intangible amortization expense was $172.7 and $165.8 for the three months ended June 30, 2023, and 2022, respectively, and $339.4 and $331.6 for the six months ended June 30, 2023, and 2022, respectively. Goodwill The change in the carrying amount of goodwill by segment is shown below: A&G IP LS&H Consolidated Total Balance as of December 31, 2022 $ 1,109.8 $ 590.3 $ 1,176.4 $ 2,876.5 Goodwill impairment (1) — (3.0) — (3.0) Impact of foreign currency fluctuations (0.2) 22.2 — 22.0 Balance as of June 30, 2023 $ 1,109.6 $ 609.5 $ 1,176.4 $ 2,895.5 (1) Recorded in connection with the assets held-for-sale and their allocated portion of the IP segment reporting unit's goodwill balance. The impairment charge is included in Goodwill and intangible asset impairments in the Condensed Consolidated Statement of Operations. Refer to Note 4 - Assets Held for Sale and Divested Operations for additional information.

Derivative Instruments

Derivative Instruments	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative InstrumentsThe Company has interest rate swap arrangements with counterparties to reduce its exposure to variability in cash flows relating to interest payments on its outstanding SOFR-based Term Loan arrangements (see Note 3 - Summary of Significant Accounting Policies for additional information). Our interest rate swap arrangements are subject to hedge accounting, by designating the interest rate swaps as hedges on applicable future quarterly interest payments. The following table provides a summary of the Company's interest rate swap arrangements by maturity date as of June 30, 2023: Notional Value Effective Date Maturity Date Fixed Rate $48.9 March 31, 2021 September 29, 2023 1.640% $48.9 April 30, 2021 September 29, 2023 1.640% $100.0 March 31, 2021 March 31, 2024 0.401% $100.0 October 31, 2022 March 31, 2024 0.421% $150.0 October 31, 2022 March 31, 2024 0.445% $384.1 August 4, 2022 October 31, 2026 2.809% $384.1 August 5, 2022 October 31, 2026 3.010% Changes in fair value are recorded in Accumulated other comprehensive income (loss) ("AOCI") in the Condensed Consolidated Balance Sheets and the amounts reclassified out of AOCI are recorded to Interest expense and amortization of debt discount, net in the Condensed Consolidated Statements of Operations. The fair value of the interest rate swaps is recorded in Other current assets or Accrued expenses and other current liabilities and Other non-current assets or Other non-current liabilities in the Condensed Consolidated Balance Sheets, according to the duration of related cash flows. The fair value of the interest rate swaps was an asset balance of $44.4 and $49.5 as of June 30, 2023 and December 31, 2022, respectively. See Note 8 - Fair Value Measurements for additional information related to the fair value of these derivative instruments. For additional information on our interest rate risk, see Item 3. Quantitative and Qualitative Disclosures about Market Risk, and see Note 9 - Debt for additional information on our outstanding Term Loan. Foreign Currency Forward Contracts The Company periodically enters into foreign currency contracts, which generally do not exceed 180 days in duration, to help manage the Company’s exposure to foreign exchange rate risks. The contracts are not designated as accounting hedges under the applicable sections of ASC 815, Derivatives and Hedging . The Company accounts for these forward contracts at fair value and recognizes the associated realized and unrealized gains and losses in Other operating income, net in the Condensed Consolidated Statements of Operations. The Company recognized a loss (gain) from the mark to market adjustment of $2.9 and $(1.0), for the three months ended June 30, 2023 and 2022, respectively, and $(0.3) and $5.7 for the six months ended June 30, 2023 and 2022 , respectively. The amounts disclosed for the three and six months ended June 30, 2022 were revised from the previously reported losses of $5.7 and $12.4, respectively. The principal amount of outstanding foreign currency contracts was $162.0 and $165.1 as of June 30, 2023 and December 31, 2022, respectively. The total fair value of the forward contracts represented an asset balance of $1.3 and $0.8, and a liability balance of $0.6 and $0.4, as of June 30, 2023 and December 31, 2022, respectively, which are classified as Other current assets and Accrued expenses and other current liabilities, respectively, in the Condensed Consolidated Balance Sheets. See Note 8 - Fair Value Measurements for additional information related to the fair value of derivative instruments.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and Liabilities Recorded at Fair Value on a Recurring Basis The following table provides a summary of the Company’s assets and liabilities that were recognized at fair value on a recurring basis as of June 30, 2023 and December 31, 2022: June 30, 2023 Level 2 Level 3 Total Assets Forward currency contracts - current $ 1.3 $ — $ 1.3 Interest rate swaps - current 13.4 — 13.4 Interest rate swaps - non-current 31.0 — 31.0 Total $ 45.7 $ — $ 45.7 Liabilities Forward currency contracts - current $ 0.6 $ — $ 0.6 Warrant liability - current — 19.2 19.2 Total $ 0.6 $ 19.2 $ 19.8 December 31, 2022 Level 2 Level 3 Total Assets Forward currency contracts - current $ 0.8 $ — $ 0.8 Interest rate swaps - current 2.3 — 2.3 Interest rate swaps - non-current 47.2 — 47.2 Total $ 50.3 $ — $ 50.3 Liabilities Forward currency contracts - current $ 0.4 $ — $ 0.4 Warrant liability - non-current — 21.0 21.0 Total $ 0.4 $ 21.0 $ 21.4 There were no transfers of assets or liabilities between levels during the six months ended June 30, 2023 or year ended December 31, 2022. Private Placement Warrants - The following table summarizes the changes in the Private Placement Warrants liability for the three and six months ended June 30, 2023 and 2022: 2023 2022 Balance as of January 1 $ 21.0 $ 227.8 Mark to market loss (gain) on financial instruments 1.1 (100.4) Exercise of Private Placement Warrants — — Balance as of March 31 $ 22.1 $ 127.4 Mark to market gain on financial instruments (2.9) (49.0) Exercise of Private Placement Warrants — — Balance as of June 30 $ 19.2 $ 78.4 Non-Financial Assets Valued on a Non-Recurring Basis The Company’s long-lived assets, including goodwill, indefinite-lived intangible and finite-lived intangible assets subject to amortization, are measured at fair value on a non-recurring basis. These assets are measured at cost but are written-down to fair value, if necessary, as a result of impairment. Finite-lived Intangible Assets - If a triggering event occurs, the Company determines the estimated fair value of finite-lived intangible assets by determining the present value of the expected cash flows. During the second quarter of 2023, the Company recorded an impairment charge of $132.2 in connection with intangible assets classified as Assets held-for-sale. The impairment charge is included in Goodwill and intangible asset impairments in the Condensed Consolidated Statement of Operations. Refer to Note 4 - Assets Held for Sale and Divested Operations for additional information.

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt The following table is a summary of the Company’s debt: June 30, 2023 December 31, 2022 Type Maturity Effective Carrying Effective Carrying Senior Notes 2029 4.875 % $ 921.4 4.875 % $ 921.4 Senior Secured Notes 2028 3.875 % 921.2 3.875 % 921.2 Revolving Credit Facility 2027 7.952 % — 7.234 % — Term Loan Facility 2026 8.217 % 2,347.4 7.384 % 2,497.4 Senior Secured Notes 2026 4.500 % 700.0 4.500 % 700.0 Finance lease 2036 6.936 % 30.8 6.936 % 31.3 Total debt outstanding 4,920.8 5,071.3 Debt discounts and issuance costs (56.5) (65.3) Current portion of long-term debt (1.1) (1.0) Long-term debt $ 4,863.2 $ 5,005.0 Financing Transactions Senior Notes (2029) and Senior Secured Notes (2028) The Company has $921.2 aggregate principal amount of its Senior Secured Notes due 2028 and $921.4 aggregate principal amount of its Senior Notes due 2029 bearing interest at a rate of 3.875% and 4.875% per annum, respectively, payable semi-annually to holders of record on June 30 and December 30 of each year. The first interest payment was paid in December 2021. Both of these series of Notes were issued by Clarivate Science Holdings Corporation (the "Issuer"), an indirect wholly-owned subsidiary of Clarivate. The Senior Secured Notes due 2028 are secured on a first-lien pari passu basis with borrowings under the existing credit facilities and Senior Secured Notes due 2026. Both of these series of Notes are guaranteed on a joint and several basis by each of Clarivate’s indirect subsidiaries that is an obligor or guarantor under Clarivate’s existing credit facilities and Senior Secured Notes due 2026. The Senior Notes due 2029 are the Issuer’s and such guarantors’ unsecured obligations. Senior Secured Notes (2026) The Company has $700.0 aggregate principal amount of its Senior Secured Notes due 2026 bearing interest at a rate of 4.50% per annum, payable semi-annually to holders of record on May 1 and November 1 of each year. The first interest payment was paid in May 2020. The Senior Secured Notes due 2026 were issued by Camelot Finance S.A. (the "Lux Issuer"), an indirect wholly-owned subsidiary of Clarivate, and are secured on a first-lien pari passu basis with borrowings under the Credit Facilities and Senior Secured Notes due 2028. These Notes are guaranteed on a joint and several basis by each of Clarivate's indirect subsidiaries that is an obligor or guarantor under the Credit Facilities and are general senior secured obligations of the Lux Issuer and are secured on a first-priority basis by the collateral now owned or hereafter acquired by the Lux Issuer and each of the guarantors that secures the Issuer’s and such guarantor’s obligations under Clarivate's credit facilities (subject to permitted liens and other exceptions). The Credit Facilities The Company's Credit Facilities consist of a $750.0 Revolving Credit Facility with a $80.0 letter of credit sublimit, due 2027, and a $2,860.0 Term Loan Facility due 2026. Revolving Credit Facility As of June 30, 2023 and December 31, 2022, the Company had no outstanding balance on its Revolving Credit Facility. The facility provides for revolving loans, same-day borrowings and letters of credit pursuant to commitments in an aggregate principal amount of $750.0 with a letter of credit sublimit of $80.0. Proceeds of loans made under the Revolving Credit Facility may be borrowed, repaid and reborrowed prior to the maturity of the Revolving Credit Facility. Our ability to draw under the Revolving Credit Facility or issue letters of credit thereunder is conditioned upon, among other things, delivery of required notices, accuracy of the representations and warranties contained in the Credit Agreement and the absence of any default or event of default under the Credit Agreement. As of June 30, 2023, letters of credit totaling $8.8 were collateralized by the Revolving Credit Facility, and, notwithstanding the Revolving Credit Facility, the Company had unsecured corporate guarantees outstanding of $13.6 and cash collateralized letters of credit of $3.6, which were not collateralized by the Revolving Credit Facility. Term Loan Facility (2026) The Company has a Term Loan Facility of $2,860.0 due 2026, which was fully drawn at closing. During the fourth quarter 2022, the Company made a $300.0 prepayment on its Term Loan Facility and prepayments of $150.0 during the six months ended June 30, 2023. Prior to the initial prepayment, the principal amount of the Term Loan Facility was repaid by the Company on the last business day of each March, June, September and December, in an amount equal to 0.25% of the aggregate original par principal amount of the initial term loans. The carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value due to the short-term nature of the interest rate benchmark rates. The fair value of the fixed rate debt is estimated based on market observable data for debt with similar prepayment features. The fair value of the Company’s debt was $4,647.4 and $4,709.6 at June 30, 2023 and December 31, 2022, respectively, and is considered Level 2 under the fair value hierarchy.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregated Revenues We disaggregate our revenues by segment (see Note 16 - Segment Information) and by transaction type based on revenue recognition pattern as follows: • Subscription-based revenues are recurring revenues that are earned under annual, evergreen or multi-year contracts pursuant to which we license the right to use our products to our customers or provide maintenance services over a contractual term. Revenues from the sale of subscription data, maintenance services, and analytics solutions are recognized ratably over the contractual period. • Re-occurring revenues are earned under contracts for specific deliverables that are typically quoted on a product, data set or project basis and often derived from repeat customers. These contracts include either evergreen clauses, in which at least six month advance notice is required prior to cancellation, or the contract is for multiple years. Deliverables are usually received by the customer instantly or in a short period of time, at which time the revenues are recognized. The most significant component of our re-occurring revenues is our 'renewal' business within CPA Global. • Transactional and other revenues are earned under contracts for specific deliverables that are typically quoted on a product, data set or project basis and often derived from repeat customers, including customers that also generate subscription-based revenues. Transactional and other revenues may involve sales to the same customer on multiple occasions but with different products or services comprising the order. Other revenues relate to professional services including implementation for software and software as a service ("SaaS") subscriptions. These contracts vary in length from several months to years for multi-year projects. Revenue is recognized over time utilizing a reasonable measure of progress depicting the satisfaction of the related performance obligation. Other revenues also includes one-time perpetual archive license revenues. The following table presents the Company’s revenues by transaction type based on revenue recognition pattern for the periods presented: Three Months Ended June 30, 2023 2022 Subscription revenues $ 406.0 $ 407.4 Re-occurring revenues 111.0 112.0 Transactional and other revenues 151.8 168.0 Deferred revenues adjustment — (0.8) Revenues, net $ 668.8 $ 686.6 Six Months Ended June 30, 2023 2022 Subscription revenues $ 799.2 $ 811.2 Re-occurring revenues 218.7 226.5 Transactional and other revenues 280.0 311.7 Deferred revenues adjustment — (0.6) Revenues, net $ 1,297.9 $ 1,348.8 Contract Balances Balances, as of: Accounts receivable, net Current Non-current December 31, 2022 $ 872.1 $ 947.5 $ 38.5 June 30, 2023 769.7 939.6 37.9 Decrease $ (102.4) $ (7.9) $ (0.6) December 31, 2021 $ 906.4 $ 1,030.4 $ 54.2 June 30, 2022 812.4 956.7 50.3 Decrease $ (94.0) $ (73.7) $ (3.9) The Company recognized revenue of $588.9 during the six months ended June 30, 2023, attributable to deferred revenues recorded at the beginning of each such period. During the three months ended June 30, 2023, we revised the disclosure in this Note by $113.9 to decrease the revenue recognized that was included in the opening deferred revenue balance to $343.9 for the three months ended March 31, 2023. This correction did not have an impact on the accompanying Condensed Consolidated Balance Sheets or Statements of Operations. Those amounts primarily consisted of subscription revenues recognized ratably over the contractual term during the respective reporting periods. Transaction Price Allocated to Remaining Performance Obligations Revenue allocated to remaining performance obligations represents the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. Our most significant remaining performance obligations relate to contracts in which we license the right to use our products to our customers or provide maintenance services over the remaining contractual term, a majority of which are contracts with a duration of one year or less. As of June 30, 2023, approximately 90% of the aggregate transaction price allocated to remaining performance obligations are expected to be satisfied within one year.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity As of June 30, 2023, there were unlimited shares of ordinary stock authorized and 676.1 million shares issued and outstanding, with no par value. The Company did not hold any shares as treasury shares as of June 30, 2023 and December 31, 2022. The Company’s ordinary shareholders are entitled to one vote per share. MCPS Offering In June 2021, concurrently with the June 2021 Ordinary Share Offering (see Note 1 - Background and Nature of Operations, in our Annual Report on Form 10-K), we completed a public offering of 14.4 million of our 5.25% Series A Mandatory Convertible Preferred Shares ("MCPS") (which included 1.9 million of our MCPS that the underwriters purchased pursuant to their option to purchase additional shares). Dividends on our mandatory convertible preferred shares are payable, as and if declared by our Board of Directors, at an annual rate of 5.25% of the liquidation preference of $100.00 per share. We may pay declared dividends on March 1, June 1, September 1 and December 1 of each year, commencing on September 1, 2021, and ending on, and including, June 1, 2024. Each of our convertible preferred shares has a liquidation preference of $100.00. As of June 30, 2023, we accrued $6.2 of preferred share dividends within Accrued expenses and other current liabilities. While the dividends on the MCPS are cumulative, they will not be paid until declared by the Company’s Board of Directors. If the dividends are not declared, they will continue to accumulate until paid, due to a backstop contained in the agreement (even if never declared). Treasury Shares CPA Global Acquisition Shares - During the six months ended June 30, 2022, 41.7 thousand shares held in the Employee Benefit Trust ("EBT"), established for the CPA Global Equity Plan, were sold at an average net price per share of $15.01 to fund the payment to the respective employees. Given the original share value of $30.99 as of the date of the acquisition, an associated loss was recognized within the Condensed Consolidated Statement of Changes in Equity in the amount of $0.7 during the six months ended June 30, 2022. The CPA Global Equity Plan was terminated during the year ended December 31, 2022 after all remaining shares were sold and payments were made to respective employees. Share Repurchase Program and Share Retirements - In February 2022, the Company's Board of Directors approved the purchase of up to $1,000.0 of the Company's ordinary shares through open-market purchases, to be executed through December 31, 2023. During the six months ended June 30, 2022, the Company repurchased 10.7 million ordinary shares at an average price per share of $16.33 with a total carrying value of $175.0 all of which were subsequently retired at an average price at retirement of $15.61 and restored as authorized but unissued ordinary shares. Upon formal retirement and in accordance with ASC Topic 505, Equity , the Company reduced its ordinary shares account by the carrying amount of the treasury shares. Additionally, given the differences of the original repurchase share value and the value at the time of formal retirements, an associated loss was recognized within the Condensed Consolidated Statement of Changes in Equity in the amount of $7.7. In May 2023, the Company's Board of Directors approved the extension of its share repurchase authorization through December 31, 2024, and reduced the authorization from $1,000.0 to $500.0. To enable the buybacks under the Board's authorization, the Company obtained shareholder approval on July 27, 2023 to permit it to conduct open-market purchases of up to 100.0 million of its ordinary shares from time to time as approved by the Board of Directors at a minimum purchase price of $1 per share and maximum purchase price of $35 per share. As of June 30, 2023, the Company had $500.0 of availability remaining under the Board's authorization. Six Months Ended June 30, 2023 2022 Total number of shares repurchased — 10.7 Average price paid per share $ — $ 16.33 Total $ — $ 175.0 Total shares retired — 10.7 Average price at retirement date $ — $ 15.61 Total $ — $ 167.3

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation The Company grants share-based awards under the Clarivate Plc 2019 Incentive Award Plan ("the Plan"). As of June 30, 2023, approximately 24.8 million of the Company’s ordinary shares were available for share-based awards. The Plan provides for the issuance of stock options, restricted stock units ("RSUs"), and performance share units ("PSUs"). Share-based compensation expense is recorded to the “Cost of revenues" and “Selling, general and administrative” line items on the accompanying Consolidated Statements of Operations. Total share-based compensation expense for the three and six months ended June 30, 2023 and 2022, comprised of the following: Three Months Ended June 30, 2023 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 10.2 $ 0.1 $ — $ 10.3 Selling, general and administrative costs — 16.2 4.0 — 20.2 Total share-based compensation expense $ — $ 26.4 $ 4.1 $ — $ 30.5 Six Months Ended June 30, 2023 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 23.0 $ 0.3 $ — $ 23.3 Selling, general and administrative costs 1.9 32.9 13.6 — 48.4 Total share-based compensation expense $ 1.9 $ 55.9 $ 13.9 $ — $ 71.7 Three Months Ended June 30, 2022 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 7.5 $ 0.1 $ (0.2) $ 7.4 Selling, general and administrative costs — 12.6 0.9 0.8 14.3 Total share-based compensation expense $ — $ 20.1 $ 1.0 $ 0.6 $ 21.7 Six Months Ended June 30, 2022 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 17.1 $ 0.3 $ (0.6) $ 16.8 Selling, general and administrative costs — 28.8 1.9 0.9 31.6 Total share-based compensation expense $ — $ 45.9 $ 2.2 $ 0.3 $ 48.4 The following table summarizes the Company’s existing share-based compensation awards program activity for the six months ended June 30, 2023, and 2022, respectively: Six Months Ended June 30, 2023 Stock Options RSUs PSUs Balance at December 31, 2022 3.7 13.5 2.1 Granted — 5.6 1.5 Exercised/Vested — (2.5) (0.1) Forfeited — (0.9) (0.5) Balance at June 30, 2023 3.7 15.7 3.0 Total remaining unamortized compensation costs $ — $ 97.6 $ 45.8 Weighted average remaining service period 0 years 1.07 years 2.21 years Six Months Ended June 30, 2022 Stock Options RSUs PSUs Balance at December 31, 2021 4.8 4.5 1.4 Granted — 4.5 0.9 Exercised/Vested (0.2) (2.0) — Forfeited (0.1) (0.4) (0.1) Balance at June 30, 2022 4.5 6.6 2.2 Total remaining unamortized compensation costs $ — $ 72.1 $ 9.4 Weighted average remaining service period 0 years 1.43 years 1.69 years

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We compute our provision for income taxes by applying the estimated annual effective tax rate to year-to-date income from recurring operations and adjust the provision for discrete tax items recorded in the period. During the three months ended June 30, 2023, the income tax benefit of $35.3 was primarily due to the mix of taxing jurisdictions in which pre-tax profits and losses were recognized, $33.0 tax benefit was associated with the impairment of intangible assets, and $17.1 tax benefit was related to the partial release of valuation allowance recorded against certain US tax attributes that are now considered realizable due to sufficient cumulative income and continued projections of future taxable income. During the three months ended June 30, 2022, the income tax provision of $10.5 was primarily due to the mix of taxing jurisdictions in which pre-tax profits and losses were recognized. During the six months ended June 30, 2023, the income tax benefit of $98.9 was primarily due to the mix of taxing jurisdictions in which pre-tax profits and losses were recognized, $70.4 tax benefit was recorded on the settlement of an open tax dispute, $33.0 tax benefit was associated with the impairment of intangible assets, and $17.1 tax benefit was related to the partial release of valuation allowance recorded against certain US tax attributes that are now considered realizable due to sufficient cumulative income and continued projections of future taxable income. During the six months ended June 30, 2022, the income tax provision of $26.8 was primarily due to the mix of taxing jurisdictions in which pre-tax profits and losses were recognized and tax expense on the mark to market gain on private warrants.

Earnings per Share

Earnings per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings per Share	Earnings Per ShareBasic net earnings per ordinary share from continuing operations (“EPS”) is calculated by taking Net income (loss) available to ordinary shareholders divided by the weighted average number of ordinary shares outstanding for the applicable period. Diluted net EPS is computed by taking net earnings adjusted for the effect of the fair value of Private Placement Warrants divided by the weighted average number of ordinary shares outstanding increased by the number of additional shares which have a dilutive effect. Potential ordinary shares on a gross basis of 30.7 million and 9.7 million options, RSUs, PSUs, and Warrants related to the 2019 Incentive Award Plan were excluded from diluted EPS for the six months ended June 30, 2023 and 2022, respectively, as their inclusion would have been anti-dilutive or their performance metric was not met. Potential ordinary shares on a gross basis of 30.0 million and 10.1 million options, RSUs, PSUs, and Warrants related to the 2019 Incentive Award Plan were excluded from diluted EPS for the three months ended June 30, 2023 and 2022, respectively, as their inclusion would have been anti-dilutive or their performance metric was not met. See Note 11 - Shareholders’ Equity and Note 12 - Share-based Compensation for additional information. The potential dilutive effect of our MCPS outstanding during the period was calculated using the if-converted method assuming the conversion as of the earliest period reported or at the date of issuance, if later. The resulting weighted-average ordinary shares of 55.3 million related to our MCPS are not included in the dilutive weighted-average ordinary shares outstanding calculation for the three and six months ended June 30, 2023, as their effect would be anti-dilutive. The basic and diluted EPS computations for our ordinary shares are calculated as follows: Three Months Ended June 30, 2023 2022 Basic EPS Net (loss) income available to ordinary shareholders $ (123.1) $ 62.4 Dividends on preferred shares 18.6 18.7 Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 Basic weighted-average number of ordinary shares outstanding 675.9 674.3 Basic EPS $ (0.21) $ 0.06 Diluted EPS Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 Change in fair value of private placement warrants — (46.8) Net loss attributable to ordinary shares, diluted $ (141.7) $ (3.1) Denominator: Shares used in computing net income (loss) attributable to per share to ordinary shareholders, basic 675.9 674.3 Weighted-average effect of potentially dilutive shares to purchase ordinary shares — 4.1 Diluted weighted-average number of ordinary shares outstanding 675.9 678.4 Diluted EPS $ (0.21) $ 0.00 Six Months Ended June 30, 2023 2022 Basic EPS Net (loss) income available to ordinary shareholders $ (79.6) $ 131.9 Dividends on preferred shares 37.4 37.4 Net (loss) income attributable to ordinary shares $ (117.0) $ 94.5 Basic weighted-average number of ordinary shares outstanding 675.4 678.3 Basic EPS $ (0.17) $ 0.14 Diluted EPS Net (loss) income attributable to ordinary shares $ (117.0) $ 94.5 Change in fair value of private placement warrants — (141.7) Net loss attributable to ordinary shares, diluted $ (117.0) $ (47.2) Denominator: Shares used in computing net income (loss) attributable to per share to ordinary shareholders, basic 675.4 678.3 Weighted-average effect of potentially dilutive shares to purchase ordinary shares — 4.9 Diluted weighted-average number of ordinary shares outstanding 675.4 683.2 Diluted EPS $ (0.17) $ (0.07)

Other Operating Expense (Income

Other Operating Expense (Income), Net	6 Months Ended
	Jun. 30, 2023
Other Income and Expenses [Abstract]
Other Operating Expense (Income), Net	Other Operating Expense (Income), Net Other operating expense (income), net, consisted of the following for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, 2023 2022 Net foreign exchange loss (gain) 11.7 (23.5) Miscellaneous expense (income), net 2.8 (1.1) Other operating expense (income), net $ 14.5 $ (24.6) Six Months Ended June 30, 2023 2022 Gain on legal settlement (1) (49.4) — Net foreign exchange loss (gain) 32.3 (43.9) Miscellaneous (income) expense, net (0.4) 5.6 Other operating income, net $ (17.5) $ (38.3) (1) Refer to Note 17 - Commitments and Contingencies for further information.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information The Chief Executive Officer is the Company’s Chief Operating Decision Maker (“CODM”). The CODM evaluates segment performance based primarily on revenue and Adjusted EBITDA. The CODM does not review assets by segment for the purposes of assessing performance or allocating resources. Below is the overview of the product groups within each reportable segment. This structure enables a sharp focus on cross-selling opportunities within the markets we serve and provides substantial scale. • The A&G segment consists of our Academia & Government product group, which drives research excellence across institutions, empower researchers to tackle today’s global challenges, and help academic institutions and libraries improve operational efficiency and effectiveness. • The IP segment consists of our Patent Intelligence, Brand IP Intelligence, and IP Lifecycle Management product groups, which enable customers to establish, protect, and manage their intellectual property. • The LS&H segment consists of our Life Sciences & Healthcare product group, which includes products and solutions that provide insight and foresight across the drug and device lifecycle, empowering life science and healthcare organizations to create a healthier tomorrow. Each of the three segments represent the segments for which discrete financial information is available and upon which operating results are regularly evaluated by the CODM in order to assess performance and allocate resources. The CODM evaluates performance based primarily on segment revenue and Adjusted EBITDA. Adjusted EBITDA represents net income (loss) before the provision for income taxes, depreciation and amortization, and interest expense adjusted to exclude acquisition and disposal-related transaction costs, losses on extinguishment of debt, share-based compensation, unrealized foreign currency remeasurement, transformational and restructuring expenses, acquisition-related adjustments to deferred revenues prior to the adoption of FASB ASU No. 2021-08 in 2021, non-operating income or expense, the impact of certain non-cash mark-to-market adjustments on financial instruments, legal settlements, impairments, and other items that are included in net income (loss) for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period. Revenues, net by segment The following table summarizes revenue by reportable segment for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government $ 342.0 $ 332.7 $ 656.7 $ 644.5 Intellectual Property 216.3 238.4 425.4 480.2 Life Sciences & Healthcare 110.5 115.5 215.8 224.1 Total Revenues, net $ 668.8 $ 686.6 $ 1,297.9 $ 1,348.8 Adjusted EBITDA by segment The following table presents segment profitability and a reconciliation to net income for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government $ 146.8 $ 122.9 $ 272.2 $ 227.4 Intellectual Property 100.1 107.8 194.7 225.4 Life Sciences & Healthcare 38.0 43.7 70.7 83.9 Total Adjusted EBITDA $ 284.9 $ 274.4 $ 537.6 $ 536.7 Benefit (provision) for income taxes 35.3 (10.5) 98.9 (26.8) Depreciation and amortization (178.1) (175.6) (350.7) (352.0) Interest expense and amortization of debt discount, net (73.0) (62.3) (146.6) (121.8) Mark to market gain on financial instruments (1) 2.9 49.0 1.8 149.4 Deferred revenues adjustment — (0.8) — (0.6) Transaction related costs (2) (0.7) (5.1) (2.4) (11.8) Share-based compensation expense (30.5) (22.1) (71.7) (59.1) Restructuring and lease impairments (3) (12.2) (19.2) (21.6) (30.9) Goodwill and intangible asset impairments (4) (135.2) — (135.2) — Other (5) (16.5) 34.6 10.3 48.8 Net (loss) income $ (123.1) $ 62.4 $ (79.6) $ 131.9 Dividends on preferred shares (18.6) (18.7) (37.4) (37.4) Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 $ (117.0) $ 94.5 (1) Reflects mark-to-market adjustments on the Private Placement Warrants under ASC 815, Derivatives and Hedging . Refer to Note 8 - Fair Value Measurements for further information. (2) Includes costs incurred to complete business combination transactions, including acquisitions, dispositions, and capital market activities and include advisory, legal, and other professional and consulting costs. (3) Primarily reflects severance and related benefit costs related to approved restructuring programs. Refer to Note 19 - Restructuring and Lease Impairments for further information. (4) Primarily includes the intangible assets impairment recorded during the three months ended June 30, 2023 further discussed in Note 4 - Assets Held for Sale and Divested Operations (5) The current year periods primarily include net losses on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. The current year-to-date period was offset by a gain on legal settlement. The prior year periods include net gains on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. Refer to Note 15 - Other Operating Expense (Income), Net and Note 17 - Commitments and Contingencies for further information.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company does not have any recorded or unrecorded guarantees of the indebtedness of others. Lawsuits and Legal Claims The Company is engaged in various legal proceedings, claims, audits, and investigations that have arisen in the ordinary course of business. These matters may include among others, antitrust/competition claims, intellectual property infringement claims, employment matters, and commercial matters. The outcome of all of the matters against the Company is subject to future resolution, including the uncertainties of litigation. From time to time, we are involved in litigation in the ordinary course of our business, including claims or contingencies that may arise related to matters occurring prior to our acquisition of businesses. At the present time, primarily because the matters are generally in early stages, we can give no assurance as to the outcome of any pending litigation to which we are currently a party, and we are unable to determine the ultimate resolution of these matters or the effect they may have on us. Our best estimate of the Company's potential liability for the larger legal claims is approximately $4, which includes estimated legal costs and accrued interest. The recorded probable loss is an estimate and the actual costs arising from our litigation could be materially lower or higher. We have and will continue to vigorously defend ourselves against these claims. We maintain appropriate levels of insurance, which we expect are likely to provide coverage for some of these liabilities or other losses that may arise from these litigation matters. During the six months ended June 30, 2023, we reached settlement related to the potential liability for one of the larger legal claims, which was covered by insurance. We recognized a total gain on settlement of $49.4 which is included in Other operating expense (income), net in the Condensed Consolidated Statement of Operations. Between January and March 2022, three putative securities class action complaints were filed in the United States District Court for the Eastern District of New York against Clarivate and certain of its executives and directors alleging that there were weaknesses in the Company’s internal controls over financial reporting and financial reporting procedures that it failed to disclose in violation of federal securities law. The complaints were consolidated into a single proceeding on May 18, 2022. On August 8, 2022, plaintiffs filed a consolidated amended complaint, seeking damages on behalf of a putative class of shareholders who acquired Clarivate securities between July 30, 2020, and February 2, 2022, and/or acquired Clarivate common or preferred shares in connection with offerings on June 10, 2021, or Clarivate common shares in connection with a September 13, 2021, offering. The amended complaint, like the prior complaints, references an error in the accounting treatment of an equity plan included in the Company’s 2020 business combination with CPA Global that was disclosed on December 27, 2021, and related restatements issued on February 3, 2022, of certain of the Company’s previously issued financial statements; the amended complaint also alleges that the Company and certain of its executives and directors made false or misleading statements relating to the Company’s product quality and expected organic revenues and organic growth rate, and that they failed to disclose significant known changes to the Company’s business model. Defendants moved to dismiss the amended complaint on October 7, 2022. Without deciding the motion, the court entered an order on June 23, 2023 allowing plaintiffs limited leave to amend, and plaintiffs filed an amended complaint on July 14, 2023. The Company intends to seek dismissal of the amended complaint. On June 7, 2022, a class action was filed in Pennsylvania state court in the Court of Common Pleas of Philadelphia asserting claims under the Securities Act of 1933, based on substantially similar allegations, with respect to alleged misstatements and omissions in the offering documents for two issuances of Clarivate ordinary shares in June and September 2021. The Company moved to stay this proceeding on August 19, 2022, and filed its preliminary objections to the state court complaint on October 21, 2022. Briefing on defendants' preliminary objections was completed on December 12, 2022, and the preliminary objections remain pending. On January 4, 2023, the court granted a partial stay of all proceedings until further court order after oral argument on the stay motion. Following oral argument on April 11, 2023, the court denied a further stay of the proceedings on April 17, 2023. Clarivate does not believe that the claims alleged in the complaints have merit and will vigorously defend against them. Given the early stage of the proceedings, we are unable to estimate the reasonably possible loss or range of loss, if any, arising from these matters. Warrant Liabilities Under Accounting Standards Codification 815, Derivatives and Hedging, ("ASC 815"), warrant instruments that do not meet the criteria to be considered indexed to an entity's own stock shall be initially classified as a liability at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash. In periods subsequent to issuance, changes in the estimated fair value of the liabilities are reported through earnings. As of June 30, 2023, the Private Placement Warrants are set to expire within one year. Therefore, the remaining liability is included in Accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheet as of June 30, 2023 (refer to Note 8 - Fair Value Measurements for additional information). Contingent Liabilities As of June 30, 2023 and December 31, 2022, there were no outstanding contingent liabilities. MCPS Dividends As noted in Note 11 - Shareholders’ Equity, dividends on our convertible preferred shares will be payable on a cumulative basis when, as and if declared by our Board of Directors, or an authorized committee of our Board of Directors, at an annual rate of 5.25% of the liquidation preference of $100.00 per share. Refer to Note 11 - Shareholders’ Equity for further details.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsOn December 1, 2021, Clarivate closed its acquisition of ProQuest from CIG, Atairos and certain other equity holders (the "Seller Group"). The aggregate consideration included $1,094.9 from the issuance of 46.9 million ordinary shares to the Seller Group. As part of the acquisition, and as a result, CIG is a related party to Clarivate. Clarivate assumed a Finance lease in which CIG is the Lessor as part of the acquisition. For the three and six months ended June 30, 2023, interest expense of $0.6 and $1.1, respectively, and amortization of the Finance lease right of use asset ("ROU") of $0.1 and $0.2, respectively, is reflected in the Condensed Consolidated Statements of Operations. The Finance lease ROU asset of $8.0 is presented within Property, Plant, and Equipment (see Note 5 - Property and Equipment, Net) and the corresponding lease liability of $30.8 is treated as an item of indebtedness (see Note 9 - Debt) within the Condensed Consolidated Balance Sheet. Clarivate has a vendor and customer arrangement with an affiliate of one of our directors. The Company recognized revenues, net of $0.2 and $0.2 and incurred expenses of $1.3 and $1.2, respectively during the three months ended June 30, 2023 and 2022, related to the arrangement. During the six months ended June 30, 2023 and 2022, the Company recognized revenues, net of $0.4 and $0.4 and incurred expenses of $2.5 and $2.3, respectively, related to the arrangement. As of June 30, 2023 and December 31, 2022, the Company had no outstanding receivables and payables related to the arrangement.

Restructuring and Lease Impairm

Restructuring and Lease Impairments	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Lease Impairments	Restructuring and Lease Impairments One Clarivate Program - During the second quarter of 2021, the Company approved a restructuring plan to streamline operations within targeted areas of the Company to reduce operational costs, with the primary cost savings driver being from a reduction in workforce. ProQuest Acquisition Integration Program - D uring the fourth quarter of 2021, the Company approved a restructuring plan to streamline operations within targeted areas of the Company to reduce operational costs, with the primary cost savings driver being from a reduction in workforce. Segment Optimization Program - During the second quarter of 2023, the Company approved a restructuring plan to streamline operations within targeted areas of the Company to reduce operational costs, with the primary cost savings driver being from a reduction in workforce. Other Restructuring Programs - During the fourth quarter of 2019 and throughout 2020, we engaged a strategic consulting firm to assist us in optimizing our structure and cost base, resulting in the implementation of several cost-saving and margin improvement programs designed to generate substantial incremental cash flows. The following table summarizes the pre-tax charges by activity and program during the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Severance and Related Benefit Costs: One Clarivate Program $ — $ 5.5 $ — $ 11.1 ProQuest Acquisition Integration Program 7.6 7.7 16.9 12.0 Segment Optimization Program 2.3 — 2.3 — Other Restructuring Programs — (1.1) — (0.7) Total Severance and Related Benefit Costs $ 9.9 $ 12.1 $ 19.2 $ 22.4 Exit and Disposal Costs: One Clarivate Program — — — — ProQuest Acquisition Integration Program $ — $ 0.1 $ 0.1 $ 1.9 Segment Optimization Program — — — — Other Restructuring Programs — 0.2 — 0.1 Total Exit and Disposal Costs $ — $ 0.3 $ 0.1 $ 2.0 Lease Abandonment Costs: One Clarivate Program — — — — ProQuest Acquisition Integration Program — 6.2 — 6.2 Segment Optimization Program 2.3 — 2.3 — Other Restructuring Programs — 0.6 — 0.3 Total Lease Abandonment Costs $ 2.3 $ 6.8 $ 2.3 $ 6.5 Restructuring and Lease Impairment Costs $ 12.2 $ 19.2 $ 21.6 $ 30.9 The following table summarizes the pre-tax charges by program and segment during the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government: One Clarivate Program $ — $ 3.2 $ — $ 6.1 ProQuest Acquisition Integration Program 4.2 8.0 9.3 11.3 Segment Optimization 1.6 — 1.6 — Other Restructuring Programs — 0.2 — — Total Academia & Government $ 5.8 $ 11.4 $ 10.9 $ 17.4 Intellectual Property: One Clarivate Program $ — $ 1.1 $ — $ 3.0 ProQuest Acquisition Integration Program 1.9 4.0 4.6 5.9 Segment Optimization 1.4 — 1.4 — Other Restructuring Programs — (0.4) — (0.2) Total Intellectual Property $ 3.3 $ 4.7 $ 6.0 $ 8.7 Life Sciences & Healthcare: One Clarivate Program $ — $ 1.2 $ — $ 2.0 ProQuest Acquisition Integration Program 1.5 2.0 3.1 2.9 Segment Optimization 1.6 — 1.6 — Other Restructuring Programs — (0.1) — (0.1) Total Life Sciences & Healthcare $ 3.1 $ 3.1 $ 4.7 $ 4.8 Restructuring and Lease Impairment Costs $ 12.2 $ 19.2 $ 21.6 $ 30.9 The following table summarizes the activity relating to the restructuring reserves across each of Clarivate's cost-saving programs during the periods indicated: Severance and Exit, Disposal Total Reserve Balance as of December 31, 2022 $ 11.5 $ 0.1 $ 11.6 Expenses recorded 19.2 2.4 21.6 Payments made (23.4) (1.5) (24.9) Noncash items (2.7) (0.8) (3.5) Reserve Balance as of June 30, 2023 $ 4.6 $ 0.2 $ 4.8 Reserve Balance as of December 31, 2021 $ 28.3 $ 0.7 $ 29.0 Expenses recorded 22.4 8.5 30.9 Payments made (34.6) (2.7) (37.3) Noncash items (2.6) (5.4) (8.0) Reserve Balance as of June 30, 2022 $ 13.5 $ 1.1 $ 14.6

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Effective July 12, 2023, the Company entered into €100.0 of cross-currency swaps designated as hedges of euro denominated net investments in subsidiaries to mitigate FX exposure. The Company expects these swaps to qualify for hedge accounting. Management has evaluated the impact of events that have occurred subsequent to June 30, 2023. Based on this evaluation, other than disclosed within these Condensed Consolidated Financial Statements and related notes, the Company has determined no other events were required to be recognized or disclosed.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net income (loss)	$ (123.1)	$ 43.5	$ 62.4	$ 69.5	$ (79.6)	$ 131.9

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Newly Adopted Accounting Standards and Recently Issued Accounting Standards	Newly Adopted Accounting Standards In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform between March 12, 2020 and December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope , which provides additional optional guidance on the transition from LIBOR to include derivative instruments that use an interest rate for margining, discounting or contract price alignment. The standard will ease, if warranted, the requirements for accounting for the future effects of the rate reform. Additionally, in December 2022, the FASB issued ASU 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024 to align with the amended cessation date of LIBOR. In 2020, the Company adopted ASU 2020-04, and, upon meeting the specified criteria in the guidance, elected the optional expedients for its interest rate swaps and debt agreements with reference to LIBOR. Accordingly, the Company has continued to account for its interest rate swaps in accordance with hedge accounting and has not applied modification accounting to its debt agreements. ASU 2021-01 and ASU 2022-06 did not have an effect on how the Company accounts for its interest rate swaps and debt agreements due to our election and application of the optional expedients discussed above in connection with ASU 2020-04. During the second quarter of 2023, the Company modified the contractual terms of its interest rate swaps and debt agreements to replace the previous LIBOR-based reference rate with the Term SOFR (Secured Overnight Financing Rate). The Company utilized the practical expedients set forth in Topic 848 and has continued to account for its interest rate swaps in accordance with hedge accounting and has not applied modification accounting to its debt instruments. Recently Issued Accounting Standards There were no other new accounting standards or updates issued or effective as of June 30, 2023, that have, or are expected to have, a material impact on the Company's Condensed Consolidated Financial Statements.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: June 30, December 31, 2023 2022 Computer hardware $ 49.3 $ 45.1 Leasehold improvements 15.6 16.1 Furniture, fixtures and equipment 42.0 39.0 Capital office leases - finance lease asset 8.0 8.0 Other 2.2 2.1 Total property and equipment, gross $ 117.1 $ 110.3 Accumulated depreciation (66.4) (55.8) Total property and equipment, net $ 50.7 $ 54.5

Other Intangible Assets, net _2

Other Intangible Assets, net and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets	The following tables summarize the gross carrying amounts and accumulated amortization of the Company’s identifiable intangible assets by major class: June 30, 2023 December 31, 2022 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Finite-lived intangible assets: Customer relationships $ 7,778.4 $ (994.7) $ 6,783.7 $ 7,809.0 $ (821.5) $ 6,987.5 Databases and content 2,733.7 (889.7) 1,844.0 2,681.0 (780.5) 1,900.5 Computer software 828.2 (469.2) 359.0 765.1 (422.2) 342.9 Other 88.7 (45.9) 42.8 88.8 (38.9) 49.9 Finite-lived intangible assets $ 11,429.0 $ (2,399.5) $ 9,029.5 $ 11,343.9 $ (2,063.1) $ 9,280.8 Indefinite-lived intangible assets: Trade names 156.9 — 156.9 156.9 — 156.9 Total intangible assets $ 11,585.9 $ (2,399.5) $ 9,186.4 $ 11,500.8 $ (2,063.1) $ 9,437.7
Schedule of Change in the Carrying Amount of Goodwill	The change in the carrying amount of goodwill by segment is shown below: A&G IP LS&H Consolidated Total Balance as of December 31, 2022 $ 1,109.8 $ 590.3 $ 1,176.4 $ 2,876.5 Goodwill impairment (1) — (3.0) — (3.0) Impact of foreign currency fluctuations (0.2) 22.2 — 22.0 Balance as of June 30, 2023 $ 1,109.6 $ 609.5 $ 1,176.4 $ 2,895.5 (1) Recorded in connection with the assets held-for-sale and their allocated portion of the IP segment reporting unit's goodwill balance. The impairment charge is included in Goodwill and intangible asset impairments in the Condensed Consolidated Statement of Operations. Refer to Note 4 - Assets Held for Sale and Divested Operations for additional information.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of the Company's assets and liabilities that were recognized at fair value on a recurring basis	The following table provides a summary of the Company’s assets and liabilities that were recognized at fair value on a recurring basis as of June 30, 2023 and December 31, 2022: June 30, 2023 Level 2 Level 3 Total Assets Forward currency contracts - current $ 1.3 $ — $ 1.3 Interest rate swaps - current 13.4 — 13.4 Interest rate swaps - non-current 31.0 — 31.0 Total $ 45.7 $ — $ 45.7 Liabilities Forward currency contracts - current $ 0.6 $ — $ 0.6 Warrant liability - current — 19.2 19.2 Total $ 0.6 $ 19.2 $ 19.8 December 31, 2022 Level 2 Level 3 Total Assets Forward currency contracts - current $ 0.8 $ — $ 0.8 Interest rate swaps - current 2.3 — 2.3 Interest rate swaps - non-current 47.2 — 47.2 Total $ 50.3 $ — $ 50.3 Liabilities Forward currency contracts - current $ 0.4 $ — $ 0.4 Warrant liability - non-current — 21.0 21.0 Total $ 0.4 $ 21.0 $ 21.4 Private Placement Warrants - The following table summarizes the changes in the Private Placement Warrants liability for the three and six months ended June 30, 2023 and 2022: 2023 2022 Balance as of January 1 $ 21.0 $ 227.8 Mark to market loss (gain) on financial instruments 1.1 (100.4) Exercise of Private Placement Warrants — — Balance as of March 31 $ 22.1 $ 127.4 Mark to market gain on financial instruments (2.9) (49.0) Exercise of Private Placement Warrants — — Balance as of June 30 $ 19.2 $ 78.4

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The following table is a summary of the Company’s debt: June 30, 2023 December 31, 2022 Type Maturity Effective Carrying Effective Carrying Senior Notes 2029 4.875 % $ 921.4 4.875 % $ 921.4 Senior Secured Notes 2028 3.875 % 921.2 3.875 % 921.2 Revolving Credit Facility 2027 7.952 % — 7.234 % — Term Loan Facility 2026 8.217 % 2,347.4 7.384 % 2,497.4 Senior Secured Notes 2026 4.500 % 700.0 4.500 % 700.0 Finance lease 2036 6.936 % 30.8 6.936 % 31.3 Total debt outstanding 4,920.8 5,071.3 Debt discounts and issuance costs (56.5) (65.3) Current portion of long-term debt (1.1) (1.0) Long-term debt $ 4,863.2 $ 5,005.0

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenues	The following table presents the Company’s revenues by transaction type based on revenue recognition pattern for the periods presented: Three Months Ended June 30, 2023 2022 Subscription revenues $ 406.0 $ 407.4 Re-occurring revenues 111.0 112.0 Transactional and other revenues 151.8 168.0 Deferred revenues adjustment — (0.8) Revenues, net $ 668.8 $ 686.6 Six Months Ended June 30, 2023 2022 Subscription revenues $ 799.2 $ 811.2 Re-occurring revenues 218.7 226.5 Transactional and other revenues 280.0 311.7 Deferred revenues adjustment — (0.6) Revenues, net $ 1,297.9 $ 1,348.8 The following table summarizes revenue by reportable segment for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government $ 342.0 $ 332.7 $ 656.7 $ 644.5 Intellectual Property 216.3 238.4 425.4 480.2 Life Sciences & Healthcare 110.5 115.5 215.8 224.1 Total Revenues, net $ 668.8 $ 686.6 $ 1,297.9 $ 1,348.8
Schedule of contract balances	Balances, as of: Accounts receivable, net Current Non-current December 31, 2022 $ 872.1 $ 947.5 $ 38.5 June 30, 2023 769.7 939.6 37.9 Decrease $ (102.4) $ (7.9) $ (0.6) December 31, 2021 $ 906.4 $ 1,030.4 $ 54.2 June 30, 2022 812.4 956.7 50.3 Decrease $ (94.0) $ (73.7) $ (3.9)

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Class of Treasury Stock	Six Months Ended June 30, 2023 2022 Total number of shares repurchased — 10.7 Average price paid per share $ — $ 16.33 Total $ — $ 175.0 Total shares retired — 10.7 Average price at retirement date $ — $ 15.61 Total $ — $ 167.3

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Total share-based compensation expense for the three and six months ended June 30, 2023 and 2022, comprised of the following: Three Months Ended June 30, 2023 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 10.2 $ 0.1 $ — $ 10.3 Selling, general and administrative costs — 16.2 4.0 — 20.2 Total share-based compensation expense $ — $ 26.4 $ 4.1 $ — $ 30.5 Six Months Ended June 30, 2023 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 23.0 $ 0.3 $ — $ 23.3 Selling, general and administrative costs 1.9 32.9 13.6 — 48.4 Total share-based compensation expense $ 1.9 $ 55.9 $ 13.9 $ — $ 71.7 Three Months Ended June 30, 2022 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 7.5 $ 0.1 $ (0.2) $ 7.4 Selling, general and administrative costs — 12.6 0.9 0.8 14.3 Total share-based compensation expense $ — $ 20.1 $ 1.0 $ 0.6 $ 21.7 Six Months Ended June 30, 2022 Stock Options RSUs PSUs CPA Global Equity Plan Total Cost of revenues $ — $ 17.1 $ 0.3 $ (0.6) $ 16.8 Selling, general and administrative costs — 28.8 1.9 0.9 31.6 Total share-based compensation expense $ — $ 45.9 $ 2.2 $ 0.3 $ 48.4
Share-based Payment Arrangement, Activity	The following table summarizes the Company’s existing share-based compensation awards program activity for the six months ended June 30, 2023, and 2022, respectively: Six Months Ended June 30, 2023 Stock Options RSUs PSUs Balance at December 31, 2022 3.7 13.5 2.1 Granted — 5.6 1.5 Exercised/Vested — (2.5) (0.1) Forfeited — (0.9) (0.5) Balance at June 30, 2023 3.7 15.7 3.0 Total remaining unamortized compensation costs $ — $ 97.6 $ 45.8 Weighted average remaining service period 0 years 1.07 years 2.21 years Six Months Ended June 30, 2022 Stock Options RSUs PSUs Balance at December 31, 2021 4.8 4.5 1.4 Granted — 4.5 0.9 Exercised/Vested (0.2) (2.0) — Forfeited (0.1) (0.4) (0.1) Balance at June 30, 2022 4.5 6.6 2.2 Total remaining unamortized compensation costs $ — $ 72.1 $ 9.4 Weighted average remaining service period 0 years 1.43 years 1.69 years

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of basic and diluted EPS computations for our common stock	The basic and diluted EPS computations for our ordinary shares are calculated as follows: Three Months Ended June 30, 2023 2022 Basic EPS Net (loss) income available to ordinary shareholders $ (123.1) $ 62.4 Dividends on preferred shares 18.6 18.7 Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 Basic weighted-average number of ordinary shares outstanding 675.9 674.3 Basic EPS $ (0.21) $ 0.06 Diluted EPS Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 Change in fair value of private placement warrants — (46.8) Net loss attributable to ordinary shares, diluted $ (141.7) $ (3.1) Denominator: Shares used in computing net income (loss) attributable to per share to ordinary shareholders, basic 675.9 674.3 Weighted-average effect of potentially dilutive shares to purchase ordinary shares — 4.1 Diluted weighted-average number of ordinary shares outstanding 675.9 678.4 Diluted EPS $ (0.21) $ 0.00 Six Months Ended June 30, 2023 2022 Basic EPS Net (loss) income available to ordinary shareholders $ (79.6) $ 131.9 Dividends on preferred shares 37.4 37.4 Net (loss) income attributable to ordinary shares $ (117.0) $ 94.5 Basic weighted-average number of ordinary shares outstanding 675.4 678.3 Basic EPS $ (0.17) $ 0.14 Diluted EPS Net (loss) income attributable to ordinary shares $ (117.0) $ 94.5 Change in fair value of private placement warrants — (141.7) Net loss attributable to ordinary shares, diluted $ (117.0) $ (47.2) Denominator: Shares used in computing net income (loss) attributable to per share to ordinary shareholders, basic 675.4 678.3 Weighted-average effect of potentially dilutive shares to purchase ordinary shares — 4.9 Diluted weighted-average number of ordinary shares outstanding 675.4 683.2 Diluted EPS $ (0.17) $ (0.07)

Other Operating Expense (Inco_2

Other Operating Expense (Income), Net (Tables)	6 Months Ended
	Jun. 30, 2023
Other Income and Expenses [Abstract]
Schedule of other operating income, net	Other operating expense (income), net, consisted of the following for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, 2023 2022 Net foreign exchange loss (gain) 11.7 (23.5) Miscellaneous expense (income), net 2.8 (1.1) Other operating expense (income), net $ 14.5 $ (24.6) Six Months Ended June 30, 2023 2022 Gain on legal settlement (1) (49.4) — Net foreign exchange loss (gain) 32.3 (43.9) Miscellaneous (income) expense, net (0.4) 5.6 Other operating income, net $ (17.5) $ (38.3) (1) Refer to Note 17 - Commitments and Contingencies for further information.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Revenue by reportable segment	The following table presents the Company’s revenues by transaction type based on revenue recognition pattern for the periods presented: Three Months Ended June 30, 2023 2022 Subscription revenues $ 406.0 $ 407.4 Re-occurring revenues 111.0 112.0 Transactional and other revenues 151.8 168.0 Deferred revenues adjustment — (0.8) Revenues, net $ 668.8 $ 686.6 Six Months Ended June 30, 2023 2022 Subscription revenues $ 799.2 $ 811.2 Re-occurring revenues 218.7 226.5 Transactional and other revenues 280.0 311.7 Deferred revenues adjustment — (0.6) Revenues, net $ 1,297.9 $ 1,348.8 The following table summarizes revenue by reportable segment for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government $ 342.0 $ 332.7 $ 656.7 $ 644.5 Intellectual Property 216.3 238.4 425.4 480.2 Life Sciences & Healthcare 110.5 115.5 215.8 224.1 Total Revenues, net $ 668.8 $ 686.6 $ 1,297.9 $ 1,348.8
Schedule of Segment Reporting Information, by Segment	The following table presents segment profitability and a reconciliation to net income for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government $ 146.8 $ 122.9 $ 272.2 $ 227.4 Intellectual Property 100.1 107.8 194.7 225.4 Life Sciences & Healthcare 38.0 43.7 70.7 83.9 Total Adjusted EBITDA $ 284.9 $ 274.4 $ 537.6 $ 536.7 Benefit (provision) for income taxes 35.3 (10.5) 98.9 (26.8) Depreciation and amortization (178.1) (175.6) (350.7) (352.0) Interest expense and amortization of debt discount, net (73.0) (62.3) (146.6) (121.8) Mark to market gain on financial instruments (1) 2.9 49.0 1.8 149.4 Deferred revenues adjustment — (0.8) — (0.6) Transaction related costs (2) (0.7) (5.1) (2.4) (11.8) Share-based compensation expense (30.5) (22.1) (71.7) (59.1) Restructuring and lease impairments (3) (12.2) (19.2) (21.6) (30.9) Goodwill and intangible asset impairments (4) (135.2) — (135.2) — Other (5) (16.5) 34.6 10.3 48.8 Net (loss) income $ (123.1) $ 62.4 $ (79.6) $ 131.9 Dividends on preferred shares (18.6) (18.7) (37.4) (37.4) Net (loss) income attributable to ordinary shares $ (141.7) $ 43.7 $ (117.0) $ 94.5 (1) Reflects mark-to-market adjustments on the Private Placement Warrants under ASC 815, Derivatives and Hedging . Refer to Note 8 - Fair Value Measurements for further information. (2) Includes costs incurred to complete business combination transactions, including acquisitions, dispositions, and capital market activities and include advisory, legal, and other professional and consulting costs. (3) Primarily reflects severance and related benefit costs related to approved restructuring programs. Refer to Note 19 - Restructuring and Lease Impairments for further information. (4) Primarily includes the intangible assets impairment recorded during the three months ended June 30, 2023 further discussed in Note 4 - Assets Held for Sale and Divested Operations (5) The current year periods primarily include net losses on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. The current year-to-date period was offset by a gain on legal settlement. The prior year periods include net gains on foreign exchange re-measurement and other individually insignificant items that do not reflect our ongoing operating performance. Refer to Note 15 - Other Operating Expense (Income), Net and Note 17 - Commitments and Contingencies for further information.

Restructuring and Lease Impai_2

Restructuring and Lease Impairments (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table summarizes the pre-tax charges by activity and program during the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Severance and Related Benefit Costs: One Clarivate Program $ — $ 5.5 $ — $ 11.1 ProQuest Acquisition Integration Program 7.6 7.7 16.9 12.0 Segment Optimization Program 2.3 — 2.3 — Other Restructuring Programs — (1.1) — (0.7) Total Severance and Related Benefit Costs $ 9.9 $ 12.1 $ 19.2 $ 22.4 Exit and Disposal Costs: One Clarivate Program — — — — ProQuest Acquisition Integration Program $ — $ 0.1 $ 0.1 $ 1.9 Segment Optimization Program — — — — Other Restructuring Programs — 0.2 — 0.1 Total Exit and Disposal Costs $ — $ 0.3 $ 0.1 $ 2.0 Lease Abandonment Costs: One Clarivate Program — — — — ProQuest Acquisition Integration Program — 6.2 — 6.2 Segment Optimization Program 2.3 — 2.3 — Other Restructuring Programs — 0.6 — 0.3 Total Lease Abandonment Costs $ 2.3 $ 6.8 $ 2.3 $ 6.5 Restructuring and Lease Impairment Costs $ 12.2 $ 19.2 $ 21.6 $ 30.9 The following table summarizes the pre-tax charges by program and segment during the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Academia & Government: One Clarivate Program $ — $ 3.2 $ — $ 6.1 ProQuest Acquisition Integration Program 4.2 8.0 9.3 11.3 Segment Optimization 1.6 — 1.6 — Other Restructuring Programs — 0.2 — — Total Academia & Government $ 5.8 $ 11.4 $ 10.9 $ 17.4 Intellectual Property: One Clarivate Program $ — $ 1.1 $ — $ 3.0 ProQuest Acquisition Integration Program 1.9 4.0 4.6 5.9 Segment Optimization 1.4 — 1.4 — Other Restructuring Programs — (0.4) — (0.2) Total Intellectual Property $ 3.3 $ 4.7 $ 6.0 $ 8.7 Life Sciences & Healthcare: One Clarivate Program $ — $ 1.2 $ — $ 2.0 ProQuest Acquisition Integration Program 1.5 2.0 3.1 2.9 Segment Optimization 1.6 — 1.6 — Other Restructuring Programs — (0.1) — (0.1) Total Life Sciences & Healthcare $ 3.1 $ 3.1 $ 4.7 $ 4.8 Restructuring and Lease Impairment Costs $ 12.2 $ 19.2 $ 21.6 $ 30.9 The following table summarizes the activity relating to the restructuring reserves across each of Clarivate's cost-saving programs during the periods indicated: Severance and Exit, Disposal Total Reserve Balance as of December 31, 2022 $ 11.5 $ 0.1 $ 11.6 Expenses recorded 19.2 2.4 21.6 Payments made (23.4) (1.5) (24.9) Noncash items (2.7) (0.8) (3.5) Reserve Balance as of June 30, 2023 $ 4.6 $ 0.2 $ 4.8 Reserve Balance as of December 31, 2021 $ 28.3 $ 0.7 $ 29.0 Expenses recorded 22.4 8.5 30.9 Payments made (34.6) (2.7) (37.3) Noncash items (2.6) (5.4) (8.0) Reserve Balance as of June 30, 2022 $ 13.5 $ 1.1 $ 14.6

Assets Held for Sale and Dive_2

Assets Held for Sale and Divested Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Finite-lived intangible asets		$ 9,029.5	$ 9,029.5		$ 9,280.8
Proceeds from divestitures, net of cash and restricted cash		10.5	10.5	$ 0
Customer relationships
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Finite-lived intangible asets		6,783.7	6,783.7		$ 6,987.5
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group within IP Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Intangible assets held for sale		26.1	26.1
Impairment of finite-lived intangible assets		132.2
Deferred tax liabilities held for sale		6.5	6.5
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group within IP Segment | Customer relationships
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Finite-lived intangible asets		$ 158	$ 158
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group within IP Segment | Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price	$ 34
Purchase price period payable	10 years

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Capital office leases - finance lease asset	$ 8		$ 8		$ 8
Total property and equipment, gross	117.1		117.1		110.3
Accumulated depreciation	(66.4)		(66.4)		(55.8)
Total property and equipment, net	50.7		50.7		54.5
Depreciation	5.4	$ 9.8	11.3	$ 20.4
Computer hardware
Property, Plant and Equipment [Line Items]
Total computer hardware and other property	49.3		49.3		45.1
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total computer hardware and other property	15.6		15.6		16.1
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total computer hardware and other property	42		42		39
Other
Property, Plant and Equipment [Line Items]
Total computer hardware and other property	$ 2.2		$ 2.2		$ 2.1

Other Intangible Assets, net _3

Other Intangible Assets, net and Goodwill - Intangible Assets by Major Class (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Goodwill And Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 11,429	$ 11,343.9
Finite-lived intangible assets, Accumulated Amortization	(2,399.5)	(2,063.1)
Total finite-lived intangible assets	9,029.5	9,280.8
Total intangible assets, Gross	11,585.9	11,500.8
Total intangible assets	9,186.4	9,437.7
Trade names
Goodwill And Intangible Assets [Line Items]
Indefinite-lived intangible assets:	156.9	156.9
Customer relationships
Goodwill And Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	7,778.4	7,809
Finite-lived intangible assets, Accumulated Amortization	(994.7)	(821.5)
Total finite-lived intangible assets	6,783.7	6,987.5
Databases and content
Goodwill And Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	2,733.7	2,681
Finite-lived intangible assets, Accumulated Amortization	(889.7)	(780.5)
Total finite-lived intangible assets	1,844	1,900.5
Computer software
Goodwill And Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	828.2	765.1
Finite-lived intangible assets, Accumulated Amortization	(469.2)	(422.2)
Total finite-lived intangible assets	359	342.9
Other Intangible Assets
Goodwill And Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	88.7	88.8
Finite-lived intangible assets, Accumulated Amortization	(45.9)	(38.9)
Total finite-lived intangible assets	$ 42.8	$ 49.9

Other Intangible Assets - Narra

Other Intangible Assets - Narratives (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 172.7	$ 165.8	$ 339.4	$ 331.6

Other Intangible Assets, net _4

Other Intangible Assets, net and Goodwill - Change in the Carrying Amount of Goodwill (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Goodwill [Roll Forward]
Goodwill, beginning balance		$ 2,876.5
Impact of foreign currency fluctuations		22
Goodwill, ending balance	$ 2,895.5	2,895.5
Goodwill impairment charge		(3)
A&G Segment
Goodwill [Roll Forward]
Goodwill, beginning balance		1,109.8
Impact of foreign currency fluctuations		(0.2)
Goodwill, ending balance	1,109.6	1,109.6
Goodwill impairment charge		0
IP Segment
Goodwill [Roll Forward]
Goodwill, beginning balance		590.3
Impact of foreign currency fluctuations		22.2
Goodwill, ending balance	609.5	609.5
Goodwill impairment charge	(3)
LS&H Segment
Goodwill [Roll Forward]
Goodwill, beginning balance		1,176.4
Impact of foreign currency fluctuations		0
Goodwill, ending balance	$ 1,176.4	1,176.4
Goodwill impairment charge		$ 0

Derivative Instruments (Details

Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Interest Rate Swap, Effective Date March 31, 2021, Fixed Rate 1.695%
Derivative Instruments
Notional Value	$ 48.9		$ 48.9
Fixed Rate	1.64%		1.64%
Interest Rate Swap, Effective Date August 5, 2022, Fixed Rate 3.063%
Derivative Instruments
Notional Value	$ 384.1		$ 384.1
Fixed Rate	3.01%		3.01%
Interest Rate Swap, Effective Date August 4, 2022, Fixed Rate 2.857%
Derivative Instruments
Notional Value	$ 384.1		$ 384.1
Fixed Rate	2.809%		2.809%
Interest Rate Swap, Effective Date April 30, 2021, Fixed Rate 1.695%
Derivative Instruments
Notional Value	$ 48.9		$ 48.9
Fixed Rate	1.64%		1.64%
Interest Rate Swap, Effective Date October 31, 2022, Fixed Rate 0.487%
Derivative Instruments
Notional Value	$ 150		$ 150
Fixed Rate	0.445%		0.445%
Interest Rate Swap, Effective Date March 31, 2021, Fixed Rate 0.451%
Derivative Instruments
Notional Value	$ 100		$ 100
Fixed Rate	0.401%		0.401%
Interest Rate Swap, Effective Date October 31, 2022, Fixed Rate 0.471%
Derivative Instruments
Notional Value	$ 100		$ 100
Fixed Rate	0.421%		0.421%
Interest rate swap
Derivative Instruments
Interest rate swap asset - non-current	$ 44.4		$ 44.4		$ 49.5
Foreign Exchange Contract
Derivative Instruments
Notional Value	162		162		165.1
Loss (gain) from the mark to market adjustment	$ 2.9	$ (1)	(0.3)	$ 5.7
Foreign Exchange Contract | Previously Reported
Derivative Instruments
Loss (gain) from the mark to market adjustment		$ 5.7		$ 12.4
Foreign Exchange Contract | Maximum
Derivative Instruments
Term of contract	180 days
Foreign exchange forward
Derivative Instruments
Interest rate swap asset - non-current	$ 1.3		1.3		0.8
Derivative Liability	$ 0.6		$ 0.6		$ 0.4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and liabilities that were recognized at fair value on a recurring basis (Details) - Recurring - USD ($) $ in Millions	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Assets
Total	$ 45.7		$ 50.3
Liabilities
Warrant liability	19.2		21
Total	19.8		21.4
Level 2
Assets
Total	45.7		50.3
Liabilities
Total	0.6		0.4
Level 3
Liabilities
Warrant liability	19.2	$ 22.1	21	$ 78.4	$ 127.4	$ 227.8
Total	19.2		21
Foreign exchange forward
Assets
Forward currency contracts asset - current	1.3		0.8
Liabilities
Forward currency contracts liability - current	0.6		0.4
Foreign exchange forward | Level 2
Assets
Forward currency contracts asset - current	1.3		0.8
Liabilities
Forward currency contracts liability - current	0.6		0.4
Interest rate swap asset
Assets
Interest rate swap asset - current	13.4		2.3
Interest rate swap asset - non-current	31		47.2
Interest rate swap asset | Level 2
Assets
Interest rate swap asset - current	13.4		2.3
Interest rate swap asset - non-current	$ 31		$ 47.2

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Private Placement Warrants Liabilities (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Mark to market gain on financial instruments	$ (2.9)		$ (49)		$ (1.8)	$ (149.4)
Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		$ 21			21
Ending balance	19.2				19.2
Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	22.1	21	127.4	$ 227.8	21	227.8
Mark to market gain on financial instruments	(2.9)	1.1	(49)	(100.4)
Ending balance	$ 19.2	$ 22.1	$ 78.4	$ 127.4	$ 19.2	$ 78.4

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill impairment charge		$ (3)
IP Segment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill impairment charge	$ (3)
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group within IP Segment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets	$ 132.2

Debt - Summary of Debt (Details

Debt - Summary of Debt (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Finance lease, effective interest rate	6.936%	6.936%
Finance lease, carrying value	$ 30.8	$ 31.3
Total debt outstanding	4,920.8	5,071.3
Debt discounts and issuance costs	(56.5)	(65.3)
Current portion of long-term debt	(1.1)	(1)
Long-term debt	$ 4,863.2	$ 5,005
Senior Notes
Debt Instrument [Line Items]
Effective Interest Rate	4.875%	4.875%
Carrying Value	$ 921.4	$ 921.4
Senior Secured Notes
Debt Instrument [Line Items]
Effective Interest Rate	3.875%	3.875%
Carrying Value	$ 921.2	$ 921.2
Revolving Credit Facility
Debt Instrument [Line Items]
Effective Interest Rate	7.952%	7.234%
Carrying Value	$ 0	$ 0
Term Loan Facility
Debt Instrument [Line Items]
Effective Interest Rate	8.217%	7.384%
Carrying Value	$ 2,347.4	$ 2,497.4
Senior Secured Notes
Debt Instrument [Line Items]
Effective Interest Rate	4.50%	4.50%
Carrying Value	$ 700	$ 700

Debt - Financing Transactions,

Debt - Financing Transactions, Senior Notes (2029) and Senior Secured Notes (2028) - (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Senior Secured Notes
Debt Instrument [Line Items]
Debt face amount	$ 921.2
Interest rate (as a percent)	3.875%	3.875%
Senior Notes
Debt Instrument [Line Items]
Debt face amount	$ 921.4
Interest rate (as a percent)	4.875%	4.875%

Debt - Financing Transactions_2

Debt - Financing Transactions, Senior Secured Notes (2026) (Details) - Senior Secured Notes - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument, Redemption
Aggregate principal amount	$ 700	$ 700
Effective Interest Rate	4.50%	4.50%

Debt - The Credit Facilities, R

Debt - The Credit Facilities, Revolving Credit Facility and Term Loan Facility (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2023
Debt Instrument [Line Items]
Fair vale of company's debt	$ 4,709.6	$ 4,647.4
Revolving Credit Facility
Debt Instrument [Line Items]
Collateralized amount		8.8
Letter of credit
Debt Instrument [Line Items]
Collateralized amount		3.6
Revolving Credit Facility
Debt Instrument [Line Items]
Sublimit		750
Aggregate principal amount	0	0
Letter of credit
Debt Instrument [Line Items]
Sublimit		80
Term Loan Facility
Debt Instrument [Line Items]
Aggregate principal amount	2,497.4	2,347.4
Repayment of long-term debt	300	$ 150
Redemption (as a percent)		0.25%
Debt face amount		$ 2,860
Senior Unsecured Notes
Debt Instrument [Line Items]
Collateralized amount		13.6
Senior Secured Notes
Debt Instrument [Line Items]
Aggregate principal amount	$ 700	$ 700

Revenue - Disaggregated Revenue

Revenue - Disaggregated Revenues and Cost to Obtain a Contract (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of revenues
Deferred revenues adjustment	$ 0	$ (0.8)	$ 0	$ (0.6)
Total revenues, net	668.8	686.6	1,297.9	1,348.8
Subscription revenues
Disaggregation of revenues
Total revenues, gross	406	407.4	799.2	811.2
Re-occurring Revenues
Disaggregation of revenues
Total revenues, gross	111	112	218.7	226.5
Transaction revenues
Disaggregation of revenues
Total revenues, gross	$ 151.8	$ 168	$ 280	$ 311.7

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022
Accounts receivable, net
Accounts Receivables - Opening	$ 872.1	$ 872.1	$ 906.4
Accounts Receivables - Closing		769.7	812.4
Increase (decrease)		(102.4)	(94)
Current deferred revenues
Current portion of deferred revenues - Opening	947.5	947.5	1,030.4
Current portion of deferred revenues - Closing		939.6	956.7
Increase (decrease)		(7.9)	(73.7)
Non-current deferred revenues
Non-current portion of deferred revenues - Opening	38.5	38.5	54.2
Non-current portion of deferred revenues - Closing		37.9	50.3
Increase (decrease)		(0.6)	$ (3.9)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue recognized that was deferred at the beginning of the period	343.9	$ 588.9
Decrease due to error correction adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue recognized that was deferred at the beginning of the period	$ (113.9)

Revenue - Transaction Price All

Revenue - Transaction Price Allocated to the Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01	Jun. 30, 2023
Transaction Price Allocated to the Remaining Performance Obligation
Remaining performance obligation, percentage	90%
Expected timing of satisfaction, period	1 year

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 27, 2023	Oct. 01, 2021	Jun. 30, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	May 24, 2023	Feb. 07, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares, issued (in shares)						676,100,000		674,400,000
Ordinary shares, outstanding (in shares)						676,100,000		674,400,000
Ordinary shares, par value (in dollars per share)						$ 0		$ 0
Treasury Stock, Common, Shares						0		0
Number of votes per share						one
Preferred stock, dividend rate (as a percent)						5.25%		5.25%
Sale of treasury shares (in shares)							41,700
Treasury stock sold, average cost per share (in dollars per share)							$ 15.01
Treasury stock acquired, average cost per share (in dollars per share)		$ 30.99					$ 16.33
Treasury stock sold at lower than repurchase price				$ (0.3)	$ (0.6)
Stock repurchase program, authorized amount									$ 500	$ 1,000
Repurchase of ordinary shares (in shares)							10,700,000
Repurchase of ordinary shares				108.6	66.4		$ 175
Treasury stock average price at retirement date (usd per share)							$ 15.61
Stock repurchased and retired						$ 0	$ 167.3
Stock repurchase program, remaining authorized repurchase amount						$ 500
Stock repurchased and retired (in shares)							10,700,000
Open Market Purchases | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, shares authorized to be repurchased (in shares)	100,000,000
Open Market Purchases | Minimum | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized repurchases, price per share (in dollars per share)	$ 1
Open Market Purchases | Maximum | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized repurchases, price per share (in dollars per share)	$ 35
Accumulated Deficit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock sold at lower than repurchase price				(0.3)	0.7		$ 0.7
Stock repurchased and retired				$ 9.2	$ (1.5)		$ 7.7
Ordinary Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares, outstanding (in shares)				673,300,000			673,300,000
Sale of treasury shares (in shares)				0
Repurchase of ordinary shares (in shares)				6,600,000	4,100,000
Stock repurchased and retired				$ 132.5	$ 34.8
Stock repurchased and retired (in shares)				0
Dividends to preferred shareholders (in shares)				0
Series A Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued (in shares)			14,400,000
Preferred stock, dividend rate (as a percent)						5.25%
Liquidation preference (usd per share)						$ 100
Dividends accrued on our 5.25% Series A Mandatory Convertible Preferred Shares				$ 6.2		$ 6.2	$ 6.2
Series A Preferred Stock | Over-Allotment Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued (in shares)			1,900,000

Share-based Compensation - Narr

Share-based Compensation - Narrative (Details)	Jun. 30, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized grants (in shares)	24,800,000

Share-based Compensation - Shar

Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 30.5	$ 21.7	$ 71.7	$ 48.4
Stock Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	0	1.9	0
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	26.4	20.1	55.9	45.9
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	4.1	1	13.9	2.2
CPA Global Equity Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	0.6	0	0.3
Cost of revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	10.3	7.4	23.3	16.8
Cost of revenues | Stock Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	0	0	0
Cost of revenues | RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	10.2	7.5	23	17.1
Cost of revenues | PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0.1	0.1	0.3	0.3
Cost of revenues | CPA Global Equity Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	(0.2)	0	(0.6)
Selling, general and administrative costs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	20.2	14.3	48.4	31.6
Selling, general and administrative costs | Stock Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	0	1.9	0
Selling, general and administrative costs | RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	16.2	12.6	32.9	28.8
Selling, general and administrative costs | PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	4	0.9	13.6	1.9
Selling, general and administrative costs | CPA Global Equity Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 0	$ 0.8	$ 0	$ 0.9

Share-based Compensation - Opti

Share-based Compensation - Option Activity (Details) - Stock Options shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares
Number of Options
Outstanding at beginning of year (in shares)	3.7	4.8
Granted (in shares)	0	0
Exercised/Vested (in share)	0	(0.2)
Forfeited/Unexercised (in shares)	0	(0.1)
Outstanding at end of year (in shares)	3.7	4.5
Aggregate Intrinsic Value
Total remaining unamortized compensation costs | $	$ 0	$ 0
Weighted average remaining service period (in years)	0 years	0 years

Share-based Compensation - RSU

Share-based Compensation - RSU and PSU Activity (Details) - USD ($) shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
RSUs
RSUs and PSUs
Beginning of year (in shares)	13.5	4.5
Granted (in shares)	5.6	4.5
Exercised/Vested (in share)	(2.5)	(2)
Forfeited/Unexercised (in shares)	(0.9)	(0.4)
End of year (in shares)	15.7	6.6
Total remaining unamortized compensation costs	$ 97.6	$ 72.1
Weighted average remaining service period (in years)	1 year 25 days	1 year 5 months 4 days
PSUs
RSUs and PSUs
Beginning of year (in shares)	2.1	1.4
Granted (in shares)	1.5	0.9
Exercised/Vested (in share)	(0.1)	0
Forfeited/Unexercised (in shares)	(0.5)	(0.1)
End of year (in shares)	3	2.2
Total remaining unamortized compensation costs	$ 45.8	$ 9.4
Weighted average remaining service period (in years)	2 years 2 months 15 days	1 year 8 months 8 days

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
(Benefit) provision for income taxes	$ (35.3)	$ 10.5	$ (98.9)	$ 26.8
Income tax benefit due to impairment of intangible assets	33		33
Income (loss) before income taxes	(158.4)	$ 72.9	(178.5)	$ 158.7
Tax benefit recorded for a settlement of an open tax dispute			70.4
Income tax benefit due to change in deferred tax assets valuation allowance	$ 17.1		$ 17.1

Earnings per Share - Narrative

Earnings per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Warrant and Share-Based Payment Arrangement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	30	10.1	30.7	9.7
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			55.3

Earnings per Share (Details)

Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Basic EPS
Net (loss) income available to ordinary shareholders	$ (123.1)	$ 43.5	$ 62.4	$ 69.5	$ (79.6)	$ 131.9
Dividends on preferred shares	18.6		18.7		37.4	37.4
Net (loss) income attributable to ordinary shares	$ (141.7)		$ 43.7		$ (117)	$ 94.5
Basic weighted-average number of ordinary shares outstanding (in shares)	675.9		674.3		675.4	678.3
Basic EPS (usd per share)	$ (0.21)		$ 0.06		$ (0.17)	$ 0.14
Diluted EPS
Net income (loss) attributable to ordinary shares	$ (141.7)		$ 43.7		$ (117)	$ 94.5
Change in fair value of private placement warrants	0		(46.8)		0	(141.7)
Net loss attributable to ordinary shares, diluted	$ (141.7)		$ (3.1)		$ (117)	$ (47.2)
Denominator:
Shares used in computing net income (loss) attributable to per share to ordinary shareholders, basic (in shares)	675.9		674.3		675.4	678.3
Weighted-average effect of potentially dilutive shares to purchase ordinary shares (in shares)	0		4.1		0	4.9
Diluted weighted-average number of ordinary shares outstanding (in shares)	675.9		678.4		675.4	683.2
Diluted EPS (usd per share)	$ (0.21)		$ 0		$ (0.17)	$ (0.07)

Other Operating Expense (Inco_3

Other Operating Expense (Income), Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Other Income and Expenses [Abstract]
Net foreign exchange loss (gain)	$ 11.7	$ (23.5)	$ 32.3	$ (43.9)
Gain on legal settlement			(49.4)	0
Miscellaneous (income) expense, net	2.8	(1.1)	(0.4)	5.6
Other operating income, net	$ 14.5	$ (24.6)	$ (17.5)	$ (38.3)

Segment Information - Narrative

Segment Information - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Disaggregation of Revenue
Number of reportable segments	3

Segment Information - Revenue b

Segment Information - Revenue by Segment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue
Total Revenues, net	$ 668.8	$ 686.6	$ 1,297.9	$ 1,348.8
Academia & Government
Disaggregation of Revenue
Total Revenues, net	342	332.7	656.7	644.5
Intellectual Property
Disaggregation of Revenue
Total Revenues, net	216.3	238.4	425.4	480.2
LS&H Segment
Disaggregation of Revenue
Total Revenues, net	$ 110.5	$ 115.5	$ 215.8	$ 224.1

Segment Information - Adjusted

Segment Information - Adjusted EBITDA by Segment (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total Adjusted EBITDA	$ 284.9		$ 274.4		$ 537.6	$ 536.7
Benefit (provision) for income taxes	35.3		(10.5)		98.9	(26.8)
Depreciation and amortization	(178.1)		(175.6)		(350.7)	(352)
Interest expense and amortization of debt discount, net	(73)		(62.3)		(146.6)	(121.8)
Mark to market gain on financial instruments	2.9		49		1.8	149.4
Deferred revenues adjustment	0		(0.8)		0	(0.6)
Transaction related costs	(0.7)		(5.1)		(2.4)	(11.8)
Share-based compensation expense	(30.5)		(22.1)		(71.7)	(59.1)
Restructuring and lease impairments	(12.2)		(19.2)		(21.6)	(30.9)
Goodwill and intangible asset impairments	(135.2)		0		(135.2)	0
Other	(16.5)		34.6		10.3	48.8
Net (loss) income	(123.1)	$ 43.5	62.4	$ 69.5	(79.6)	131.9
Dividends on preferred shares	(18.6)		(18.7)		(37.4)	(37.4)
Net income (loss) attributable to ordinary shares	(141.7)		43.7		(117)	94.5
Academia & Government
Segment Reporting Information [Line Items]
Total Adjusted EBITDA	146.8		122.9		272.2	227.4
Restructuring and lease impairments	(5.8)		(11.4)		(10.9)	(17.4)
Intellectual Property
Segment Reporting Information [Line Items]
Total Adjusted EBITDA	100.1		107.8		194.7	225.4
Restructuring and lease impairments	(3.3)		(4.7)		(6)	(8.7)
LS&H Segment
Segment Reporting Information [Line Items]
Total Adjusted EBITDA	$ 38		$ 43.7		$ 70.7	$ 83.9

Commitments and Contingencies -

Commitments and Contingencies - Contingencies (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies
Reserve for probable claims	$ 4
Gain on settlement	49.4	$ 0
One Of The Larger Legal Claims
Commitments and Contingencies
Gain on settlement	$ 49.4

Commitments and Contingencies_2

Commitments and Contingencies - Mandatory Convertible Preferred Share Dividends (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Dividends Payable [Line Items]
Preferred stock, dividend rate (as a percent)	5.25%	5.25%
Series A Preferred Stock
Dividends Payable [Line Items]
Preferred stock, dividend rate (as a percent)	5.25%
Liquidation preference (usd per share)	$ 100

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
	Dec. 01, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party and Former Parent Transactions
Capital office leases - finance lease asset		$ 8		$ 8		$ 8
Finance lease liability		30.8		30.8		$ 31.3
Total Revenues, net		668.8	$ 686.6	1,297.9	$ 1,348.8
ProQuest
Related Party and Former Parent Transactions
Clarivate stock to be issued	$ 1,094.9
Newly issued ordinary shares (in shares)	46.9
Affiliated Entity
Related Party and Former Parent Transactions
Interest on lease liabilities		0.6		1.1
Amortization of right-of-use assets		0.1		0.2
Capital office leases - finance lease asset		8		8
Finance lease liability		30.8		30.8
Director
Related Party and Former Parent Transactions
Costs and Expenses, Related Party		1.3	1.2	2.5	2.3
Total Revenues, net		$ 0.2	$ 0.2	$ 0.4	$ 0.4

Restructuring and Lease Impai_3

Restructuring and Lease Impairments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			$ 11.6	$ 29
Expenses recorded	$ 12.2	$ 19.2	21.6	30.9
Payments made			(24.9)	(37.3)
Noncash items			(3.5)	(8)
Restructuring Reserve, Ending Balance	4.8	14.6	4.8	14.6
Academia & Government
Restructuring Reserve [Roll Forward]
Expenses recorded	5.8	11.4	10.9	17.4
Intellectual Property
Restructuring Reserve [Roll Forward]
Expenses recorded	3.3	4.7	6	8.7
Life Sciences & Healthcare
Restructuring Reserve [Roll Forward]
Expenses recorded	3.1	3.1	4.7	4.8
One Clarivate Program | Academia & Government
Restructuring Reserve [Roll Forward]
Expenses recorded	0	3.2	0	6.1
One Clarivate Program | Intellectual Property
Restructuring Reserve [Roll Forward]
Expenses recorded	0	1.1	0	3
One Clarivate Program | Life Sciences & Healthcare
Restructuring Reserve [Roll Forward]
Expenses recorded	0	1.2	0	2
ProQuest Acquisition Integration Program | Academia & Government
Restructuring Reserve [Roll Forward]
Expenses recorded	4.2	8	9.3	11.3
ProQuest Acquisition Integration Program | Intellectual Property
Restructuring Reserve [Roll Forward]
Expenses recorded	1.9	4	4.6	5.9
ProQuest Acquisition Integration Program | Life Sciences & Healthcare
Restructuring Reserve [Roll Forward]
Expenses recorded	1.5	2	3.1	2.9
Segment Optimization Program | Academia & Government
Restructuring Reserve [Roll Forward]
Expenses recorded	1.6	0	1.6	0
Segment Optimization Program | Intellectual Property
Restructuring Reserve [Roll Forward]
Expenses recorded	1.4	0	1.4	0
Segment Optimization Program | Life Sciences & Healthcare
Restructuring Reserve [Roll Forward]
Expenses recorded	1.6	0	1.6	0
Other Restructuring Plans | Academia & Government
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0.2	0	0
Other Restructuring Plans | Intellectual Property
Restructuring Reserve [Roll Forward]
Expenses recorded	0	(0.4)	0	(0.2)
Other Restructuring Plans | Life Sciences & Healthcare
Restructuring Reserve [Roll Forward]
Expenses recorded	0	(0.1)	0	(0.1)
Severance and Related Benefit Cost
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			11.5	28.3
Expenses recorded	9.9	12.1	19.2	22.4
Payments made			(23.4)	(34.6)
Noncash items			(2.7)	(2.6)
Restructuring Reserve, Ending Balance	4.6	13.5	4.6	13.5
Severance and Related Benefit Cost | One Clarivate Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	5.5	0	11.1
Severance and Related Benefit Cost | ProQuest Acquisition Integration Program
Restructuring Reserve [Roll Forward]
Expenses recorded	7.6	7.7	16.9	12
Severance and Related Benefit Cost | Segment Optimization Program
Restructuring Reserve [Roll Forward]
Expenses recorded	2.3	0	2.3	0
Severance and Related Benefit Cost | Other Restructuring Plans
Restructuring Reserve [Roll Forward]
Expenses recorded	0	(1.1)	0	(0.7)
Exit and Disposal Costs
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0.3	0.1	2
Exit and Disposal Costs | One Clarivate Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0	0	0
Exit and Disposal Costs | ProQuest Acquisition Integration Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0.1	0.1	1.9
Exit and Disposal Costs | Segment Optimization Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0	0	0
Exit and Disposal Costs | Other Restructuring Plans
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0.2	0	0.1
Lease Abandonment Costs
Restructuring Reserve [Roll Forward]
Expenses recorded	2.3	6.8	2.3	6.5
Lease Abandonment Costs | One Clarivate Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0	0	0
Lease Abandonment Costs | ProQuest Acquisition Integration Program
Restructuring Reserve [Roll Forward]
Expenses recorded	0	6.2	0	6.2
Lease Abandonment Costs | Segment Optimization Program
Restructuring Reserve [Roll Forward]
Expenses recorded	2.3	0	2.3	0
Lease Abandonment Costs | Other Restructuring Plans
Restructuring Reserve [Roll Forward]
Expenses recorded	0	0.6	0	0.3
Exit, Disposal and Abandonment Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			0.1	0.7
Expenses recorded			2.4	8.5
Payments made			(1.5)	(2.7)
Noncash items			(0.8)	(5.4)
Restructuring Reserve, Ending Balance	$ 0.2	$ 1.1	$ 0.2	$ 1.1

Subsequent Events (Details)

Subsequent Events (Details) € in Millions	Jul. 12, 2023 EUR (€)
Subsequent Event | Currency Swap | Designated as Hedging Instrument | Net Investment Hedging
Subsequent Events
Derivative, Notional Amount	€ 100